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The majority o f previous research has shown that carbohydrate (CHO) supplementation 
during continuous exercise does not spare muscle glycogen. However, much of this 
research has been performed over short periods of time (<3 hours) at moderate to high 
intensities. PURPOSE: This study evaluated the effects o f CHO supplementation on 
whole body and muscle substrate utilization during prolonged, discontinuous exercise. 
M ETHODOLOGY: Seven recreationally trained males performed a GXT on a treadmill 
(TM) and electronically braked cycle ergometer to determine ventilatory threshold (VT) 
and VOipeak In a double blind, random crossover design, subjects received either a CHO 
[20% maltodextrin (0.6g/kg FFM/hr)] or placebo (PLA) drink each hour. TM exercise 
was performed at 41 ±2% V0 2 peak, and 69±2% VT. Cycle ergometer exercise was 
performed at 42±1% VOzpeak, and 72±4% VT. Hourly exercise included 9 minutes on an 
upper body ergometer, 19 minutes on the cycle ergometer, and 2 0  minutes on the 
treadmill, followed by a 10-minute rest and feeding period. A standardized lunch (5 g/kg 
BW CHO, and 1.2 g/kg BW PRO) was provided after hour five for both trials. Muscle 
biopsies o f the vastus lateralis were performed pre- and post-exercise, and expired gases 
were collected eveiy other hour during the TM segment. Blood glucose (BG) was 
measured continuously using an indwelling glucose sensor, and total urine void was 
collected- RESULTS: The rates o f total CHO oxidation on the TM were significantly 
higher during the CHO trial (331.0±24.7, and 22L4±37.9g, for CHO and PLA, 
respectively, p=0.0001). There were no significant differences in pre-exercise glycogen 
between the trials (174.94±43.05, and 172.4^53.3 g/kg wet weight, for CHO and PLA 
respectively, p=0.7829). However, post-exercise glycogen concentration was 
significantly lower following the PLA (135.2±42.0, 109.35±32,2 g/kg wet weight, for 
CHO and PLA respectively, p=0.0274). No differences in BG or RPE between trials 
were observed. Total urinary nitrogen output was also similar for both trials 
(483.0±429.4 and 609.7±461.2 mg/dl, for CHO and PLA respectively, p=0.1696). 
CONCLUSION: These data suggest that regular CHO feedings during extended 
exercise increases whole body CHO oxidation and has a small glycogen sparing effect 
over 10 hours o f exercise. This may partially explain the ability to maintain exercise 
intensity or self-selected work rates over long periods o f activity.
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Chapter One: Introduction
Introduction
Carbohydrate (CHO) is an important fuel source for endurance activities. Sports 
nutritionists often advise athletes to consume diets that are largely composed of CHO 
(60-65% o f total energy intake) in order to provide their bodies with the fuel necessary to 
maintain intensity for long durations. Athletes are often advised to eat CHO rich foods 
prior to competition, to supplement with CHO during exercise, and replenish CHO stores 
after exercise.
Carbohydrate stored as glycogen in muscles provides the body with a quick 
energy source under anaerobic conditions. When exercise intensity increases CHO is the 
fuel source that supplies the body with the increased energy demands (Brooks 1998;
Coyle 2000; De Feo, Di Loreto et al. 2003). Fat is a more efficient fuel source, for long 
duration exercise because o f the larger numbers o f adenosine triphosphate (ATP) it can 
provide per fatty acid. Fats are also useful during extended activities as they are a slow 
burning fuel source that requires readily available O2 for oxidation (Coyle 2000; De Feo, 
Di Loreto et al. 2003). The fatty acid aerobic system , called Beta-oxidation, can be 
increased with exercise training, but there is a limit to the adaptations that occur, the rate 
o f fat oxidation and the availability o f O2. For this reason CHO supplementation is 
necessary to provide the body with energy to maintain high intensity during long duration 
endurance activities (Coggan 1997; De Feo, Di Loreto et al. 2003).
It has been well established that exogenous CHO supplementation during exercise 
increases CHO oxidation (Coyle, Hagberg et al. 1983; Coyle and Coggan 1984; Coyle 
1992; el-Sayed, MacLaren et al. 1997; Burke and Hawley 1999; Jeukendrup 2004).
Blood glucose levels are maintained, respiratory exchange ratio (RER) values remain 
elevated, muscle glycogen may be spared, rate of perceived exertion (RPE) decreases, 
hepatic glucose output is suppressed, a decrease in liver glycogenolysis, glycogen 
synthesis may occur in both muscle and liver during low intensity exercise, and there 
may be a central factor influence with CHO supplementation. Many researchers have 
shown that exogenous CHO can increase performance and time to fatigue during long 
duration exercise (Coyle and Coggan 1984; Coyle 1992; el-Sayed, MacLaren et al. 1997; 
Burke and Hawley 1999; Coyle 2000; Jeukendrup and Jentjens 2000; Hargreaves 2004; 
Jeukendrup 2004; Utter, Kang et al. 2004).
Exercise intensity affects the amount o f exogenous CHO that is oxidized.
Training related improvements in exogenous CHO oxidation occur and, it is thought that 
different mechanisms are responsible at different intensities (Gollnick, Piehl et al. 1974; 
Kuipers, Keizer et al. 1987). Maintenance o f plasma glucose and sparing o f liver 
glycogen are thought to be the main reasons for the ability to sustain performance and 
intensity during long duration exercise (Coyle, Hagberg et al. 1983; Bosch, Weltan et al. 
1996; el-Sayed, MacLaren et al. 1997; Kjaer 1998; Burke and Hawley 1999; Horowitz, 
Mora-Rodriguez et al. 1999; Meyer, Gabriel et al. 2003).
Past researchers have shown conflicting evidence concerning the sparing of 
muscle glycogen during exercise with CHO supplementation. Most research in this area 
has been performed at moderate to high intensities and for no more than 5-hours of
exercise, where the varied duration and higher intensities partially explain the mixed 
results. Tsintzas et al. (1995, 1996) looked at specific muscle fiber types in order to 
determine if  there was a difference in muscle glycogen use. These researchers have 
shown that type I fibers use much o f their glycogen stores, where type II fibers are nearly 
unaffected, indicating that there is a fiber type difference in muscle glycogen oxidation.
Researchers have shown that during intermittent exercise CHO supplementation 
has a positive effect on muscle glycogen. It is not clear if these results are due to a 
decreased glycogenolysis or if  glycogen resynthesis was able to occur during the low 
intensity periods built into the exercise (Kuipers, Keizer et al. 1987).
While little is known about the effects of carbohydrate feedings during long 
duration, low intensity exercise, or work, this knowledge can provide important 
information to individuals involved in long duration exercise or work such as ultra­
marathon, military personnel and wildland firefighters. People working in these job 
settings are sometimes required to work many hours a day for multiple days. In order to 
help promote increased work capacity and safety for these individuals, it is important to 
know the mechanisms of fatigue and decreased performance in these populations.
Problem
The purpose o f this study was to examine the effects o f exogenous CHO 
supplementation on whole body and muscle substrate utilization during long duration, 
discontinuous, low intensity exercise.
Research Hypothesis
Hypothesis One
We hypothesized that CHO feedings provided during ten hours of intermittent 
low-intensity exercise will increase whole body CHO oxidation rates.
Rationale fo r  Hypothesis One
Research in the past has demonstrated an increase in CHO oxidation rates when 
provided with exogenous sources. CHO oxidation (g-min^) and RER values have been 
shown to remain elevated, blood glucose levels are maintained, hepatic glucose output is 
suppressed, and hepatic glycogen synthesis may occur during low intensity exercise 
(Coyle, Hagberg et al. 1983; Coyle and Coggan 1984; Coyle 1992; el-Sayed, MacLaren 
et al. 1997; Burke and Hawley 1999; Jeukendrup 2004).
Hypothesis Two
We hypothesized that CHO feedings provided during ten hours o f intermittent 
low-intensity exercise would decrease muscle glycogenolysis in exercised muscle.
Rationale fo r  Hypothesis Two
Tsintzas et al. (1995, 1996) demonstrated that running at approximately 70% 
V0 2 max while provided with a 5.5% CHO-electrolyte solution demonstrated a muscle 
glycogen sparing effect. The supplementation had the largest affect on the type I fibers, 
as they were more depleted than the type II fibers. The percent change in muscle 
glycogen content was lower in the CHO trial as compared to the PLA trial. It has also
been demonstrated that for the first two hours of cycling there was no muscle glycogen 
sparing effect. After the third hour o f exercise there was a statistically significant 
reduction in the rate o f muscle glycogen utilization with CHO supplementation. Thus, 
during longer duration, low intensity exercise there may be a muscle glycogen sparing 
effect with exogenous CHO.
Significance of the Study
Previous research has addressed the issue o f muscle glycogen use during exercise, 
but most o f this research has been performed at moderate to high intensities. To our 
knowledge no researchers have looked at long duration (>5 hours), low intensity, 
intermittent exercise that can be applied to an arduous work situation. Most o f the 
previous studies have also chosen intensities that are relative to VOzpeak and not relative to 
the lactate threshold (Tlact) or ventilatory threshold (Tvent). Other researchers suggest 
that it may be more appropriate to use Tvent to prescribe exercise intensity, and that these 
measures are a better marker o f sustainable metabolic fitness.
Rationale for the Study
Conducting this study in a controlled laboratory setting may allow for a better 
understanding o f results from field research with Wildland Firefighters (WLFF) for the 
mechanisms explaining their improved performance with CHO supplementation. 
Understanding these mechanisms may also have implications for WLFF and military 
personnel meal plans, and feeding strategies. Recovery from fatigue in these populations
is also important in order for them to maintain work output and safety for multiple 
workdays. This research may provide an understanding o f the mechanisms and help us to 
develop new strategies for recovery from arduous workdays.
Limitations
i/Non-randomized sample. Subjects will not be from a randomized sample. Subjects will 
be recruited from the University of Montana campus and will be volunteer subjects.
ii/Instrumentation. There is error associated with all instrumentation. By using regularly 
calibrated equipment and trained laboratory technicians instrumentation error will be 
limited.
Hi/Physical Capacity o f  Subjects. V0 2 peak and Tvent will be different in each subject. 
This limitation was minimized by adjusting the exercise workload relative to each 
individual Tvent.
iv/Gender. The data collected will only apply to recreationally active males. 
Delimitations
i/Type o f  subjects. Only recreationally active subjects with a V0 2 peak of no less than 45 
ml kg '-min"^ will be used for the study.
ii/Speciflc exercise intensity. Subjects will exercise at 70% Tvent during the treadmill 
and cycle ergometer section of the trial.
iv/Males only. Only recreationally active males will be used for this study.
v/Age o f  subjects. Subjects will all be under the age o f 40 in order to decrease 
physiological changes that occur in substrate utilization over this age.
Definition of Terms
Rate of Perceived Exertion (RPE), The subjective level o f intensity a subject feels their 
body is exerting for any given workload during exercise. The rating is based on a 6-20 
scale, and was developed by Borg (1982).
Respiratory Exchange Ratio (RER). Expired CO2 divided by inspired O2 (VCO2/VO2), 
where V is minute volume. By using this ratio, substrate utilization can be estimated in 
g*min'^ CHO or g-min"^ fat. Based on oxygen requirements to oxidize fat and CHO, it is 
accepted that, exclusive of CO2 buffering an RER o f 0.70 demonstrates an almost 
exclusive use o f fats as a fuel source, where an RER of 1.00 demonstrates an almost 
exclusive use o f CHO as a fuel source. In practice this estimate is reliable and valid with 
an RER range o f 0.70 to 0.90
Substrate. The fuel source the body uses to produce ATP
ATP. Adenosine triphosphate. The molecular currency o f intracellular energy.
Ventilatory Threshold (Tvent). The exercise load at which expiration, and ventilated 
CO2 increases exponentially for a given increase in ventilated O2.
Ventilatory Threshold Detection Methods. Three methods were used during this 
research to determine Tvent; Ventilatory Equivalencies Method, Excess CO2 Method, and 
Modified V-Slope Method (Gaskill, Ruby et al. 2001).
Relative Intensity. Relative intensity is determined using the amount o f oxygen 
consumed for a given workload, with regard to the subject’s body weight. This allows 
for inter-subject comparison (ml kg’^-min'^). For this project, intensities are at different 
times reported relative to body weight (ml kg'^ min"'), to V0 2 peak (% V0 2 peak), or Tvent 
(% Tvent).
Absolute Intensity. Absolute intensity is determined using the amount of oxygen 
consumed for a given workload, without regard to body weight (L*min'^).
VOzmai The maximum volume o f oxygen a person can metabolize, despite an increase 
in workload.
VOzpeak- The maximum amount of oxygen a person can metabolize for any give mode of 
exercise.
Low-intensity exercise. Exercise that is performed less then 45% VOipeak- For this 
study low-intensity exercise is also defined as exercise less than 72% Tvent.
Intermittent Exercise. Exercise that is interspersed with rest periods, i.e. discontinuous 
exercise.
Long Duration Exercise. Exercise that lasts longer than 5 hours in duration.
Glycogenolysis. The catabolism of muscle and liver glycogen.
Exogenous Carbohydrate. Ingested CHO. Glucose polymers, for this study 
maltodextrin, will be ingested in order to be used as a non-glycogenolytic fuel source for 
the body.
Endogenous Carbohydrate. Glucose stores within the liver, muscle or bloodstream that 
are mainly in the form of glycogen.
Chapter Two: Review of Literature 
Metabolic Response to Exercise
The main goal o f human body metabolism during exercise is to provide adenosine 
triphosphate (ATP) for all active tissue, especially the working muscles. ATP is the 
molecule that provides the energy for the actin/myosin cross bridge to occur during 
contraction of the muscle. There are many eloquent reactions that must occur to ensure 
the production of ATP at rates high enough to allow for muscular contraction to occur 
(Coyle 2000; Thong and Graham 2002; De Feo, Di Loreto et al. 2003). The intracellular 
stores o f ATP are limited and the turnover rate for ATP in the body is high, in a normally 
functioning cell an ATP molecule will be consumed in about one minute. Higher rates of 
turnover are achieved during exercise (Brooks 1998; Febbraio and Dancey 1999; De Feo, 
Di Loreto et al. 2003).
There are two main classifications for muscle fiber types that occur in the human 
body. The two main classifications are Type I and Type II fibers. The type o f fiber that a 
muscle is largely composed of depends on the stresses that are placed on the muscle 
during training. Type I muscles fibers are often called slow, oxidative fibers. These 
fibers have a high oxidative capacity and are often utilized during endurance exercise. 
Type II muscle fibers are often called fast, glycolytic fibers. Conversely, these fibers 
have a high glycolytic capacity and are often used during short, high intensity bursts of 
exercise. There are also intermediate fiber types that demonstrate both of these 
capacities. Each o f the different fiber types have different ratios of the metabolic
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pathways that are utilized to provide energy for the working muscle (Coyle 2000; De 
Feo, Di Loreto et al. 2003).
The first metabolic pathway that is recruited during exercise is the 
ATP/phosphocreatine (ATP/PCr) system. This system transfers a phosphate group, from 
PCr to adenosine diphosphate (ADP) to form ATP, in a reaction catalyzed by creatine 
kinase. This reaction occurs in the absence o f oxygen, and is the main metabolic 
pathway that is utilized for the first 3-5 seconds o f exercise. This pathway takes place 
mostly in Type II muscle fibers and provides the body with energy for short bursts of 
exercise or for the first few seconds o f longer duration activity (De Feo, Di Loreto et al.
2003).
The second metabolic pathway that is engaged during muscle work is anaerobic 
glycolysis. This pathway is also used in the absence of oxygen and is a series o f coupled 
reactions where glycogen, or glucose is broken down to produce molecules of ATP and 
pyruvate, which can be readily converted to lactate. This pathway provides that largest 
percentage o f energy to the working muscles for approximately the first 15 seconds of 
intense exercise, and provides two molecules o f ATP per one glucose molecule. At the 
onset o f exercise catecholamines in the body are increased and glycolysis and 
glycogenolysis are upregulated to provided glucose in the form of glucose-6  phosphate 
molecules for this reaction (Kjaer 1998). This reaction occurs in the Type II, fast twitch 
muscle fibers (Brooks and Mercier 1994; Febbraio and Dancey 1999; De Feo, Di Loreto 
et al. 2003), and to a smaller extent the Type I fibers.
The last metabolic pathway that is activated to provide energy to working muscles 
is oxidative phosphorylation. In this pathway fats, CHO, and protein (PRO) are
11
completely oxidized into CO2 and H2O. Due to the increase in catecholamines during 
longer duration exercise there is an increase in lipolysis that provides fat molecules for 
this metabolic pathway, as well as increased glycolysis resulting in pyruvate to fuel 
oxidative phosphorylation. This reaction takes place in the inner membrane of the 
mitochondria, where hydrogen ions are pumped across the membrane to form an 
electrochemical gradient. This gradient allows for ATP synthase to add a phosphate 
group to ADP to regenerate ATP for working muscles. This metabolic pathway is the 
most efficient at providing ATP to working muscles, because it can provide around 130 
ATP molecules per fat molecule or 36 ATP molecules per glucose molecule that is 
oxidized completely to CO2 and H2O. This reaction occurs most often in the Type I, slow 
oxidative muscle fibers (Brooks and Mercier 1994; Brooks 1998; De Feo, Di Loreto et al.
2003).
Fat and CHO are the primary fuel sources for working muscles during exercise, 
but lactate is also metabolized by oxidative phosphorylation. As exercise intensity 
increases there is an abundance of excess pyruvate formed which is converted to lactate, 
and transported out o f the active muscle cells. The increase o f pyruvate is due to an 
increased glycolytic flux causing more pyruvate to be produced than can be consumed 
through the Kreb’s cycle (Brooks 1998; De Feo, Di Loreto et al. 2003). This excess 
lactate is transported via the so called “lactate shuttle” to oxidative muscle cells where is 
it used directly as a fuel source. Alternatively, excess lactate can also be used to 
regenerate glucose molecules through gluconeogenesis in the liver (Brooks and Mercier 
1994; Coggan 1997; Kjaer 1998; De Feo, Di Loreto et al. 2003).
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It is widely accepted that as exercise intensity and duration increase the reliance 
on CHO also increases (Brooks and Mercier 1994; Coggan 1997). This concept has been 
described by Brooks et al. (1994) as the “crossover concept”. In this theory it is stated 
that at low intensity activity fats can provide up to 60% o f all fuel sources for energy. As 
intensity o f activity increases there is a greater reliance on CHO as a fuel source, until a 
“crossover” point is reached where the primary fuel source becomes CHO. Near 
maximum exercise intensity, CHO provides 100% of the energy to maintain exercise. 
This theory has received criticism since its introduction in 1994. The main reason for 
controversy is that this crossover concept is based on absolute values o f VOzpeak. In this 
theory mild, moderate and hard exercise intensities are defined by percent VOzpeak- This 
theory states that endurance training reduces CHO oxidation at “mild” to “moderate” 
intensities, but that this adaptation does not occur at “hard” intensities. There is a large 
body o f data that does not support this concept, including training induced decreases in 
RER, reduced muscle glycogen utilization, reduced glucose utilization, increase plasma 
FFA and increased intramuscular triglyceride (IMTG) utilization. These conflicts 
demonstrate the inconsistencies within the crossover concept as it is used to describe the 
increase in CHO oxidation during increasing intensity exercise (Coggan 1997).
Muscle Glycogen Utilization during Exercise
The importance of muscle glycogen during exercise in humans has been studied 
for many decades. In 1967 Bergstrom was able to establish the importance o f muscle 
glycogen as a fuel source during exercise with the introduction of the muscle biopsy.
This allowed for direct measure o f muscle glycogen content in samples (Bergstrom and
13
Hultman 1967). In recent years it has been discovered that levels o f muscle glycogen 
content may play an important role in substrate metabolism and the onset o f fatigue 
during exercise (Febbraio and Dancey 1999; Hargreaves 2004; Johnson, Stannard et al.
2004).
There are two pathways in which glucose can enter the muscle cells, either 
through contraction mediated or insulin mediated pathways. Both mediated uptakes rely 
on the same seven-transmembrane protein, known as the glucose transport protein 
(GLUT 4). After glucose enters a cell it either undergoes oxidation through glycolysis or 
storage through glycogen synthesis (Thong and Graham 2002; Hargreaves 2004; 
Hargreaves, Hawley et al. 2004). It has been shown that exercise at low intensities can 
allow for both of these pathways to occur simultaneously. The explanation for this may 
be that different fiber types are recruited at different times during exercise or at varying 
intensities, and this would allow for resynthesis to occur in one fiber type while 
glycolysis is occurring in another. Different muscle fiber types may rely on different fuel 
sources to produce ATP for energy. During long duration, low intensity exercise 
multiple fiber types are recruited in order to maintain exercise. As a result o f this more 
glycogen depletion may occur across a range of muscle tissues (Gollnick, Piehl et al. 
1974; Price, Taylor et al. 1994; Tsintzas, Williams et al. 1995; Tsintzas, Williams et al. 
1996; Tsintzas and Williams 1998).
The rate of glycogenolysis during exercise depends on the intensity o f exercise. 
Total glycogen use depends on both the intensity and the duration o f exercise. 
Glycogenolysis occurs at higher rates during intense exercise to provide the working 
muscles with the increased CHO that is needed to maintain the high intensity, at the onset
14
of exercise initial glycogenolysis is high and slows down as the muscle achieves 
homeostasis as the duration of exercise increases (Bergstrom and Hultman 1967; 
Hargreaves 1997; Watt, Heigenhauser et al. 2002; Hargreaves 2004). Price et al. (1994) 
demonstrated that after the initial decrease in glycogen content, during extended, low 
intensity exercise. A steady state was achieved in which glycogen synthesis and 
glycogenolysis occurred at equal rates. However, the methodology in this study did not 
consider the possibility that these two phenomena may occur simultaneously but in 
different muscle fiber types.
There are also two different molecules o f glycogen that are used at different rates 
to provide ATP for the body. These two pools are named pro- (PG) and macro-glycogen 
(MG). The physiological functions and metabolic regulation o f these two separate pools 
of glycogen have not been clearly established (Graham, Adamo et al. 2001). Graham et 
al. (2 0 0 1 ) demonstrated that pro-glycogen may be the molecule that is largely responsible 
for metabolic regulation during exercise. In this study it was demonstrated that when 
glycogenolysis decreased later in exercise it was due to a decrease in MG catabolism. 
This may also add to the explanation for a decrease in glycogenolysis later in long 
duration exercise, and during repeated bouts o f exercise.
Exogenous Carbohydrate Supplementation and Performance
A decrease in CHO availability during exercise has been shown to lead to the 
development o f fatigue in humans. CHO supplementation before or during exercise has 
been shown to improve performance and increase the time to fatigue (Coyle and Coggan
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1984; Coyle 1992; el-Sayed, MacLaren et al. 1997; Burke and Hawley 1999; Coyle 2000; 
Jeukendrup and Jentjens 2000; Hargreaves 2004; Jeukendrup 2004; Utter, Kang et al.
2004). The mechanism for this improvement is not clear, although increased rates of 
CHO oxidation are observed when exogenous CHO is available (Coyle 1992;
Jeukendrup, Saris et al. 1996; el-Sayed, MacLaren et al. 1997; Burke and Hawley 1999; 
Jeukendrup and Jentjens 2000; Meyer, Gabriel et al. 2003; Jeukendrup 2004). The 
maintenance o f blood glucose, glycogen resynthesis, sparing of liver glycogen, sparing of 
muscle glycogen, and a central stimulating mechanism for CHO have all been used to 
explain this effect (Coyle, Hagberg et al. 1983; Coyle and Coggan 1984; Coyle 1992; el- 
Sayed, MacLaren et al. 1997; Burke and Hawley 1999; Jeukendrup 2004).
Endogenous stores o f CHO are limited, and can be slightly increased with diet 
and training, but for many endurance activities CHO supplementation can provide 
additional resources to improve performance (el-Sayed, MacLaren et al. 1997; Lambert, 
Hawley et al. 1997; Schabort, Bosch et al. 1999; Smith, Rhodes et al. 2002; Jeukendrup 
2003; Hargreaves, Hawley et al. 2004). Most studies demonstrate the ergogenic effects 
o f supplemental exogenous CHO versus placebo (PLA), but some fail to show increased 
performance (Jeukendrup 2004). The reason for this may be the measure that was used to 
assess performance. It is difficult to compare the different ways that performance was 
measured in these studies, because many studies used a different measure of 
performance, or different mode of exercise (Jeukendrup 2004).
Maintenance of blood glucose is one o f the ergogenic effects o f CHO that is 
thought to increase measures o f performance. Many studies have demonstrated that with 
exogenous CHO supplementation subjects maintain blood glucose levels (Coyle,
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Hagberg et al. 1983; Coyle and Coggan 1984; el-Sayed, MacLaren et al. 1997; Sugiura 
and Kobayashi 1998; Horowitz, Mora-Rodriguez et al. 1999; Schabort, Bosch et al. 1999; 
Meyer, Gabriel et al. 2003). Coyle et al. (1983) demonstrated that the onset of fatigue 
could be delayed during exercise at 70-80% VOipeak In this study subjects were asked to 
exercise on a cycle ergometer at approximately 74% VOzpeak until volitional exhaustion. 
The exercise time to exhaustion was approximately 2-hours. Although an increase in 
time to exhaustion was demonstrated it was only observed in those subjects who showed 
a decrease in blood glucose levels during the fasted exercise trial. This early study in 
CHO supplementation would suggest that increased performance and time to onset o f 
fatigue would be accountable by maintenance of blood glucose.
Another explanation for increased performance and time to fatigue during CHO 
feedings is glycogen synthesis during exercise. Kuipers et al, (1987) observed that 
supplementation of CHO during intermittent cycling exercise allowed for glycogen 
resynthesis to occur. This active recovery demonstrated that subjects could synthesize 
glycogen at maximum resynthesis rates. Upon analysis o f the fiber type distribution in 
this study the researchers discovered that only approximately 39% of each muscle sample 
was Type II fibers. If  the glycogen synthesis rates are adjusted for the percent of Type I 
fibers they may have actually been higher in these non-active fibers at this exercise 
intensity.
At the onset o f exercise liver glycogenolysis increases in order to provide the 
body with CHO for ATP synthesis. During extended exercise, when the liver begins to 
be glycogen depleted, gluconeogenesis becomes the primary fuel source for glucose 
released into the blood from the liver (Coyle, Hagberg et al. 1983; Coyle, Coggan et al.
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1986; Kuipers, Costill et al. 1986; Coyle 1992; el-Sayed, MacLaren et al. 1997; Kjaer 
1998; Burke and Hawley 1999). Jeukendrup et al. (1999) established that with 
exogenous CHO supplementation liver glycogenolysis could be completely suppressed 
during exercise. During this study subjects were asked to ride on a cycle ergometer for 2- 
hours at approximately 50% VOipeak CHO rich in C^  ̂was provided to the subjects in 
order to determine the rates o f appearance (R@) and rate o f disappearance (R<j) o f glucose 
during the trial. Using this stable isotope method it was determined that exogenous CHO 
in moderate amounts (35g/hr) could partially suppress glycogenolysis in the liver, and in 
large amounts (175g/hr) liver glycogenolysis could be completely suppressed. An 
interesting finding was that the rate o f muscle glycogenolysis was not different between 
the two trials, indicating that this fuel source cannot be spared. The findings regarding 
muscle glycogen support previous findings by this lab (Jeukendrup, Saris et al. 1996).
There is conflicting evidence concerning the debate over muscle glycogen use 
during exercise when CHO supplementation is provided. Many researchers have 
demonstrated that there is not a muscle glycogen sparing effect when supplemental CHO 
is provided (Coyle, Coggan et al. 1986; Febbraio and Stewart 1996; van Zant and Lemon 
1997; Febbraio and Dancey 1999; McConell, Snow et al. 1999; Schabort, Bosch et al. 
1999; Karelis, Peronnet et al. 2002). Many of these studies were performed at a high 
intensity, for durations between two and four hours. Also, in some of these studies, 
subjects were in a fasted state and are not fed prior to the onset of exercise. However, 
van Sant et al. (1997) and Schabort et al. (1999) studied the effects of pre-exercise 
feeding on the rate o f muscle glycogen utilization during exercise. In each of these 
studies researchers determined that a pre-exercise meal did not affect the rate of
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glycogenolysis between the two trials. Febbraio et al. (1996) assessed the effects of 
different pre-exercise foods on glycogenolysis. In this study subjects were fed different 
glycémie index foods. Again, rates o f glycogenolysis were not statistically different 
between trials.
Some past researchers who looked directly at the effects o f CHO feedings during 
exercise found no difference in muscle glycogenolysis (Coyle, Coggan et al. 1986; 
McConell, Snow et al. 1999; Karelis, Peronnet et al. 2002). Coyle et al. (1986) reported 
no difference in muscle glycogen utilization when subjects were fed CHO during 105 
minutes o f exercise at approximately 71% VOipeak, and another trial that measured time 
to fatigue in CHO versus FLA. In the CHO trial, they found an increase in rates o f CHO 
oxidation, blood glucose, and time to volitional exhaustion. However, there was no 
difference in skeletal muscle glycogen content at the end o f the 105-minute trial. This 
study supports the finding that the rate of muscle glycogenolysis is not affected by CHO 
supplementation during moderate to high intensity exercise.
While this is true, Tsintzas et al. (1995, 1996) has performed numerous studies 
concerning specific muscle fiber types and glycogen utilization across these different 
fibers. In theses studies it is established that muscle fiber type plays a role in 
glycogenolysis (Tsintzas, Williams et al. 1995; Tsintzas, Williams et al. 1996; Tsintzas 
and Williams 1998). These studies have been performed in male runners, and it is 
thought that the reason for the sparing effect may be the mode of exercise (Jeukendrup 
and Jentjens 2000; Jeukendrup 2004). In the first of these two studies (Tsintzas, 
Williams et al. 1995) runners were asked to perform treadmill exercise for 60 minutes at 
approximately 70% VOipeak Trials were separated by at least one week. After analysis
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of pro-glycogen (PG) and macro-glycogen (MG) content in fiber types it was established 
that more glycogen was stored, pre-exercise, in Type II fibers and that depletion occurred 
more in the Type I muscle fibers. There was also a higher glycogen content in the Type I 
fibers at the end o f exercise in the CHO trial suggesting glycogen sparing in Type I 
fibers. In a second study (Tsintzas, Williams et al. 1996) subjects were asked to perform 
treadmill exercise at an intensity o f approximately 60% VOzpeak until volitional 
exhaustion. Time to fatigue in the CHO trial was significantly longer, consistent with 
findings from other labs (Coyle, Hagberg et al. 1983; Coyle and Coggan 1984; Coyle 
1992; el-Sayed, MacLaren et al. 1997; Burke and Hawley 1999; Jeukendrup and Jentjens 
2000; Hargreaves 2004; Jeukendrup 2004). During the CHO trial a muscle biopsy was 
obtained at the time that coincided with exhaustion for the FLA trial. At this time point 
there was a difference in muscle glycogen content, demonstrating higher muscle 
glycogen or reduction in glycogenolysis in the CHO trial. However, there was no 
difference in muscle glycogen content at the point o f exhaustion between the two trials.
In a similar study Bosch et al. (1996) asked subjects to cycle at approximately 
70% VOipeak for 180 minutes o f exercise. In this study it was established that there was 
an increased muscle glycogen content at the end of exercise, and in the CHO trial there 
was no net glycogen loss between hours 2 and 3. This study supports the findings of 
previous research that has demonstrated sparing of muscle glycogen during exercise 
(Tsintzas, Williams et al. 1995; Tsintzas, Williams et al. 1996).
The last mechanism thought to be responsible for the positive results in 
performance and time to fatigue is a central effect o f CHO. Carter et al. (2004) 
performed a study where subjects were asked to perform a pre-determined amount o f
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work as fast as possible. In this trial either 25 mL o f 6.4% maltodextrin solution or PLA 
was rinsed in the mouth for approximately 5 seconds and then spit out. The main finding 
in this study was that the time to completion of the predetermined work was significantly 
faster in the CHO mouth rinse trial. The mechanism for this improved performance is 
currently not known, but the theory presented in this paper is that there may be CHO 
receptors in the mouth that are associated with motivation to perform work.
To our knowledge the longest study that has been performed to assess metabolism 
during CHO supplementation has lasted five hours in duration (Jeukendrup, Moseley et 
al. 2006). In this study subjects exercised at 50% of their max watts on a cycle ergometer 
for five hours. Labeled CHO was ingested in order to determine glucose and R<i, and 
to calculate exogenous and endogenous utilization. These results were consistent with 
previous findings, and CHO oxidation was maintained throughout this long duration 
exercise trial.
Exercise Relative to Ventilatory Threshold
Much of the current research focuses on high intensity exercise that is relative to 
VOipeak- Prescribing workloads to Tlact or Tvent may be more appropriate to ensure 
similar metabolic stress across subjects and fitness levels. In this study Tvent was 
determined using three concurrent methods that have been validated to accurately assess 
Tvent (Gaskill, Ruby et al. 2001).
21
Wildland Firefighters
During long duration, arduous wildland fire suppression, Cuddy et al. (submitted 
for publication) showed that regular CHO feedings throughout a workday can improve 
work output by 28%. This research has shown that blood glucose is maintained with 
exogenous CHO, but there is no difference in Rate o f Perceived Exertion (RPE) in these 
subjects. Energy expenditure in these individuals averages 3500-6000 kcal/day (Ruby, 
Shriver et al. 2002). Individuals working in this environment perform a variety of jobs, 
including but not limited to, sawing, hiking, digging line, and swamping logs. These 
activities use both the upper and lower body. CHO feedings may help to provide a 
positive energy balance during this arduous work, and further improve performance of 
work in these populations. Further, laboratory based studies may help to validate these 
findings from the field.
Summary
Metabolic response to exercise demonstrates an increased reliance on CHO as a 
fuel source as the intensity of exercise increases. It is well established that CHO 
supplementation during exercise can improve performance and increase time to 
exhaustion through maintenance o f blood glucose, glycogen resynthesis, sparing of 
endogenous glycogen stores, and the possibility o f a central effect of CHO on reward 
centers in the brain. Studies assessing the rate o f muscle glycogenolysis during exercise 
with exogenous CHO supplementation demonstrate conflicting results. A majority o f this 
research has been performed at high intensities, for relatively short periods of time. Also,
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the exercise intensities o f this prior research are largely prescribed relative to VOipeak 
The findings from a study assessing the effects of CHO on long duration, low intensity 
exercise may have considerable application to work settings, including the Wildland 
Firefighter or military personnel.
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Chapter Three: Methodology
Setting
All exercise testing took place in the Human Performance Laboratory, in McGill 
Hall, Room 121 on the campus of the University o f Montana, Missoula, MT.
Subjects
Seven recreationally active males served as subjects for the investigation. Prior to 
participation, each subject completed an Institutional Review Board (IRB) approved 
informed consent form. Subject descriptive characteristics are shown in Table 1.
Descriptive Data
Weight, Height, and Age
Weight in Kilograms, was measured using a calibrated, digital scale (Befour Inc, 
Cedarburg, WI). Height was measured using a calibrated stadiometer with shoes 
removed.
Anthropometric Measurements
Hydrostatic weighing, at estimated residual volume (Goldman and Becklake 
1959), using a calibrated electronic under water scale (Exertech, Dresbach, MN) was 
used to determine body fat percent and fat free mass (Lohman 1992). Subjects performed
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multiple underwater weight trials until three values within 1 0 0  grams were obtained.
Body density was then used to determine body fat percent using the age specific 
equations o f Lohman (1992).
Exercise Testing
Cycle Ergometer
All subjects were asked to report to the Human Performance Laboratory after 
abstaining firom calories, nicotine, and caffeine for twelve hours prior to testing, A 
graded exercise test to volitional exhaustion, to determine maximal oxygen uptake 
(V0 2 peak) and ventilatory threshold (Tvent) was performed using an electronically braked 
Cardgirus cycle ergometer (CE) (Cardgirus, Spain). The cycle ergometer was adjusted to 
proper seat and handle bar height for each subject. All subjects performed a warm-up 
prior to testing. The testing protocol consisted o f a ramped protocol adding 40 Watts of 
resistance each minute o f the test until volitional exhaustion, or until a cadence of 50 
revolutions per minute (rpm) could not be maintained. Expired gas data were 
continuously collected and 15-second averages were analyzed using a two-way mouth 
piece (Hans Rudolph, Inc., Kansas City, MO) and a ParvoMedics metabolic cart 
(ParvoMedics, Salt Lake City, UT). Prior to each exercise test calibration was performed 
using a 3-Liter calibration syringe (Hans Rudolph, Inc., Kansas City, MO), and a 
calibration gas mixture (16.0% O2, 4.0% CO2, N2 balance) (Airgas Mid South, Inc., 
Tulsa, OK). Heart rate was measured using a chest strap heart rate transmitter and 
monitor (Polar USA, Lake Success, NY).
25
Treadmill
All subjects were asked to report to the Human Performance Laboratory after 
abstaining from calories, nicotine, and caffeine for twelve hours prior to testing. A 
graded exercise test to volitional exhaustion was performed using a Quinton Q65 
treadmill (TM) (Quinton, Seattle, WA). All subjects performed a warm-up prior to 
testing. The testing protocol consisted of a speed set at 4.0 mph with an increase in one 
percent grade every 30 seconds. At a respiratory exchange ration (RER) greater than 1.0 
the speed was increased 0.5 mph, every 30 seconds until volitional exhaustion. Expired 
gas and heart rate data were continuously collected and 15-second averages were 
analyzed as previously described for the cycle ergometer. Calibration was conducted as 
described above.
Upper Body Ergometer
After performing the graded treadmill test subjects were asked to use the 
C a rd iO zcycie  Exercise Dynamometer, upper body ergometer (UBE) (ErgometRx, St. Paul, 
MN) by simulating double or single poling during cross-country skiing. Subjects were 
asked to find a resistance equal to a rate o f perceived exertion (RPE) of 9 to 10. Watts 
were monitored throughout the trial using Extend Software (SMI, St. Cloud, MN).
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Determination of Ventilatory Threshold
Three methods were used concurrently to determine Tvent for the purpose of 
determining workload for the CE and TM segments o f exercise. The three methods were 
ventilatory equivalencies, excess CO2 production, and a modified V-slope method 
(Gaskill, Ruby et al. 2001). Two researchers evaluated each volitional test for the CE and 
TM using these three methods and determined if a clear Tvent could be established. All 
three methods for determining Tvent had to occur at the same time point in order for a 
clear Tvent to be chosen. If a clear Tvent could not be established the data were rejected 
and the test was performed again. The Tvent chosen by the two researchers were then 
compared. Both investigators had to agree on the time point chosen for Tvent or the data 
were rejected and the test was performed again. Tvent for the CE was 58.4±4.2%
VOzpeak and 60.3±4.3% VOzpeak for the TM.
Research Design and Control
Each subject performed two, 10-hour exercise trials in a double blind, random 
crossover design. Subjects received either an artificially sweetened CHO drink [20% 
maltodextrin (0.6g/kg FFM/hr)] or an artificially sweetened placebo (PLA) drink of the 
same flavor and volume each hour.
In order to ensure similar muscle glycogen levels between trials each subject was 
provided with a standardized meal plan, o f at least 5 g/kg BW CHO, and 1.2 g/kg BW 
protein for the 24 hours before each trial. Subjects were allowed to add to the meal plan,
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but each day before their trial was eucaloric, and subjects consumed the same diet 24- 
hours prior to each trial. Dietary analysis was conducted using Food Processor Nutrition 
Analysis Software (ESHA, Salem, OR). Subjects were also asked to refrain from any 
type o f sustained, or hard exercise for 24 hours before each trial.
Exercise Trial
Subjects were asked to report to the Human Performance Lab at 0500, after 
abstaining from calories, nicotine, and caffeine for twelve hours prior to testing. An 
indwelling glucose sensor (Medtronic Minimed, Northridge, CA), with a flexible catheter 
was placed in the subcutaneous fat just above the right gluteus maximus, in order to 
continuously monitor blood glucose. One hour was set for equilibration of the glucose 
sensor. A OneTouch-Ultra glucometer (LifeScan, Milpitas, CA) was used to calibrate the 
glucose sensor immediately pre-exercise, pre-lunch, and post-exercise.
Subjects were then prompted to void their bladder and a pre-exercise weight was 
obtained using a calibrated, digital scale (Befour Inc, Cedarburg, WI). A pre-exercise 
muscle biopsy was then obtained from the midsection o f the vastus lateralis. Subjects 
were placed in a supine position on a hospital bed, and the area was cleaned with 10% 
Povidine iodine swab sticks (Triad, Brookfield, WI) and draped with sterile dressings. A 
local anesthetic (1% lidocaine, lOmg/mL) was used prior to the 5mm incision in the 
vastus lateralis. A Bergstrom needle with modified suction using a three-way stopcock 
was used to obtain 75-lOOmg o f muscle tissue. Visible connective tissue and fat were
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dissected from the muscle tissue, and the sample was flash frozen in liquid nitrogen, and 
stored at -80°C for subsequent analysis.
A standardized breakfast (5 g/kg BW CHO, and 1.2 g/kg BW PRO) was provided 
post-biopsy. Average time from breakfast to exercise was recorded and was 23:08±8:35 
min for the PLA trial and 24:36±4:57 min for the CHO trial (p=0.70). Exercise began 
after equilibration and calibration o f the glucose sensor.
The exercise protocol during the ten hours consisted of a set schedule for the three 
different modes o f exercise each hour. Subjects began with UBE exercise at a self­
selected speed and constant resistance for 9 minutes. A one-minute transition was 
allowed to the CE, where exercise was performed at approximately 70% Tvent, for 19 
minutes. The actual values were 72.3±4.2% Tvent, and 42.1±1.6% VOzpeak, which was 
equivalent to 103.6±23.8 Watts. Another one-minute transition was allowed to the TM, 
where exercise was performed again at approximately 70% Tvent for 20 minutes. The 
actual values were 69 .41 .9%  Tvent, and 41.8±2.4% VOzpeak, which was at 4.0 mph and 
5.4=tl.7% grade. Following the 50 minutes o f exercise a ten-minute rest and feeding 
period (PLA or CHO of equal volume) took place. A forty-minute lunch break was 
allowed between hours 5 and 6 , where a standardized lunch (5 g/kg BW CHO, and 1.2 
g/kg BW PRO) was provided in place of the PLA/CHO feeding.
Total urine void was collected for later analysis o f urinary nitrogen, to determine 
protein metabolism throughout each trial. Heart rate was again monitored using a chest 
strap heart rate transmitter and monitor (Polar USA, Lake Success, NY) during the last 
five minutes of each hour o f CE and TM portions o f exercise. The five-minute average 
was recorded for PLA and CHO trials.
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Immediately upon completion of the tenth hour blood glucose was measured with 
a glucometer, and used to calibrate the indwelling glucose sensor. Subjects were then 
instructed to void their bladder, and a post-exercise weight was obtained. Subjects were 
again placed in a supine position on the hospital bed and a second muscle biopsy was 
obtained from a second incision in the vastus lateralis, approximately 2 cm proximal to 
the initial biopsy site on the same leg, using the previously described methods Time from 
the end of the tenth hour to biopsy was planned at 15 minutes. The actual time for biopsy 
collection was 15:59±1:22 min in the PLA trial and 16:40±1:33 min in the CHO trial.
Metabolic Data
Expired gases were collected during the initial five minutes on the CE to ensure 
that the appropriate workload o f approximately 70% Tvent was prescribed. After this 
time expired gases were only collected during the last five minutes o f the TM segment of 
the trial during hours 1 ,3 ,5 , 6 , 8 , and 10. Expired gas data were continuously collected 
during the last five minutes o f these times.
Whole Body Substrate Utilization
Whole body substrate utilization was calculated from the TM segment of exercise 
using steady state VO2 and VCO2 data. The last 2.5 minutes of expired gas data collected 
on the TM was averaged and RER was calculated. Fat oxidation (g-min'^) and CHO 
oxidation (g-min'^) were then calculated from the RER (VC0 2 A/̂ 0 2 ) data (Frayn 1983).
30
Total fat and CHO oxidation for the TM segment was determined by calculating the 
g*min^ and multiplying by 2 0  minutes for each hour.
Muscle Glycogen Assay
Muscle glycogen was analyzed using a spectrophotometric method (Infinity 
glucose reagent. Thermo Electron, Melbourne, Australia) after tissue preparation.
Samples weighing about 20 mg wet weight (actual 19.7±3.9 mg wet weight) were 
weighed upon removal from a -8 0 “C freezer. Samples were placed in lOOOpL, 1 N HCl 
solution and homogenized using a manual mortar and pestle tissue grinder. Once 
homogenized, samples were incubated at 95,6“C for three hours. After the incubation, 
500pL, 1 N NaOH was added to SOOpL of boiled tissue sample to normalize pH.
Samples were analyzed in triplicate, after pipetting 40 mL o f sample into ImL o f the 
Infinity glucose reagent and incubated at room temperature for 15 minutes, using a 
spectrophotometer (Spectronic 402, Milton Roy, Rochester, NY), against glycogen and 
glucose controls. Muscle glycogen was expressed in mmol kg wet weight-1 of muscle.
Statistical Procedures
Descriptive data were expressed as Mean±SD. A two-way ANOVA with 
repeated measures design using a series of apriori, planned comparisons were used to 
analyze data. Specific cell comparisons were performed using Super ANOVA (Abacus 
Concepts, Inc, Berkley, CA). The number o f uncorrected comparisons was limited to the
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degrees o f freedom (df) allowed. When the number o f comparisons exceeded the 
allowed df, a Bonferroni critical value procedure was performed (0.05/number o f 
comparisons). The level o f significance for the experiment was set at an overall alpha of 
0.05. All graphed values are expressed in Mean±SE.
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The reason for the unusual format o f this thesis from traditional formatting is due 
to the nature o f the manuscript. This thesis represents data that was collected as an 
individual research project. Immediately following the completion o f this study the 
methodology was duplicated in females for another separate thesis project.. It was felt 
that in order to complete a manuscript that would be allowed submission into ajournai 
the data from these two separate theses projects needed to be pooled. Chapters 1-3 and 
the appendices o f this thesis concern only the male data, while the manuscript is the sex 
comparison from the pooled data. Two separate reference lists, tables, and graphs are 
included in this thesis because o f the combined data included in the manuscript.
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Abstract
Previous research has demonstrated conflicting results regarding sex differences in 
substrate utilization during exercise. In addition, although past research has shown the 
ergogenic benefits o f exogenous carbohydrate (CHO) intake during exercise, limited 
work has been done to evaluate its effectiveness during extended exercise/work periods 
lasting longer than 4-5 hours. PURPOSE: The purpose o f the present study was to 
evaluate the effects o f CHO supplementation on whole body and muscle substrate 
utilization during 10  hours o f prolonged, discontinuous exercise in men and women. 
METHODOLOGY: Thirteen recreationally trained subjects (n=7 males, n= 6  females, 
during the follicular phase) performed a GXT on a treadmill (TM) and electronically 
braked cycle ergometer to determine ventilatory threshold (VT) and VOapeak- In a double 
blind, randomized crossover design, subjects received either a CHO [20% maltodextrin 
(0.6g-kg FFM'^'hr"^)] or flavored placebo (PLA) drink each hour. TM exercise was 
performed at 71±3% VT (44±4% VOipeak,)* Cycle ergometer exercise was performed at 
72±4% VT (42±1% VOzpeak) Hourly exercise included 9 minutes on an upper body 
ergometer, 19 minutes on a cycle ergometer, and 2 0  minutes on a treadmill, followed by a 
10-minute rest and feeding period. A standardized breakfast and lunch (5 g kg'^ CHO, 
and 1.2 g kg'^ protein) were provided for both trials. Muscle biopsies o f the vastus 
lateralis were obtained pre and post-exercise, and expired gases were collected every 
other hour during the TM segment o f the trial to establish average rates o f whole body 
CHO and fat oxidation for the first five (AM) and second five (PM) hours o f exercise. 
Blood glucose (BG) was measured continuously using an indwelling glucose sensor, and
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total urine void was collected. Data were analyzed using a mixed design ANOVA with 
repeated measures. RESULTS; Whole body CHO oxidation demonstrated a significant 
trial X time interaction (CHO: AM=138±13, PM=130±18; PLA: AM=108±17, 
PM=86±18 pmol/kg FFM/min, p<0.05. Muscle glycogenolysis was 78% higher for the 
PLA compared to the CHO trial (3.1 ±2.3 and 5.9±2.9 mmol kg"  ̂wet wt hr^ for CHO and 
PLA respectively, p<0.05). There were no significant sex specific differences in 
glycogen utilization or whole body substrate oxidation. CONCLUSION: Although the 
ingestion o f CHO during long duration exercise, appears to decrease rates o f muscle 
glycogenolysis while better maintaining whole body carbohydrate oxidation, there is 
limited differences between the sexes.
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Introduction
Paragraph 1
It has been well established that exogenous carbohydrate (CHO) supplementation during 
exercise increases and/or maintains rates o f whole body CHO oxidation In
addition, if exogenous CHO is provided, blood glucose levels are maintained RPE
often decreases hepatic glucose output is suppressed and muscle glycogenolysis 
may or may not be slowed *. It has also been conclusively demonstrated that 
exogenous CHO can increase performance and time to fatigue during exercise in both 
males and females
Paragraph 2
The majority o f past research involving the use o f supplemental CHO has been conducted 
under a variety o f exercise durations (1-5 hours) and intensities (60-80% VOzpeak) It 
appears that the longest controlled exercise trial evaluating the effects o f exogenous CHO 
is a recent study by Jeukendrup et al. (2006) where subjects exercised for a period o f 5 
hours. To our knowledge, past research has not adequately addressed the effects o f 
supplemental, exogenous CHO during exercise periods longer than five hours.
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Paragraph 3
Sex specific differences in substrate metabolism have demonstrated mixed results in past 
research. While some studies demonstrate increased rates o f fat oxidation and decreased 
muscle glycogenolysis in females others demonstrate no significant differences
between the sexes 21,23,24,32 studies demonstrate that women rely more heavily
on lipid oxidation expressed as a percentage of total energy expenditure In
studies using stable isotope dilution techniques, similar rates of glucose appearance (Ra) 
and glucose disappearance (Rd) with carbohydrate supplementation have been observed 
in both men and women, when performing exercise at the same relative intensity
Moreover, our laboratory has previously demonstrated minimal differences in whole 
body substrate oxidation and glucose kinetics across the sexes during exercise at 70 and 
90% o f the lactate threshold. However, the relative contribution of blood glucose to total 
CHO oxidation was consistently higher in females
Paragraph 4
Past researchers have demonstrated that females may oxidize substrates differently across 
the menstrual cycle and that the primary mechanism for this subtle difference is 
related to circulating estradiol When amenorrheic females were provided with
exogenous estradiol, plasma glucose Ra and Rd were reduced Interestingly, this 
finding has been duplicated when estradiol was provided to males These results 
demonstrate the importance in controlling menstrual cycle status when performing 
metabolism studies in female subjects. However, it is also important to note that the 
metabolic effects associated with the reproductive hormonal milieu are far less influential
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on substrate utilization in comparison to the effects o f exercise intensity, duration, and 
feeding and training status.
Paragraph 5
While the majority o f the past researchers have not demonstrated a decrease in muscle 
glycogenolysis when exogenous CHO is provided, the exercise durations have not been 
extended beyond 5 hours. In addition, the potential for a sex dependent metabolic 
response during extended exercise when exogenous CHO is provided has not been 
addressed. The purpose o f this study was to determine the effects o f exogenous CHO 
feedings on whole body substrate oxidation and musele glycogenolysis, during long 
duration, low intensity exercise in males and females.
Paragraph 6
We hypothesized that rates o f muscle glycogenolysis would be suppressed when CHO 
was provided during extended exercise and that there would be minimal differences in 
substrate metabolism across the sexes.
Methodology
Subjects 
Paragraph 7
Thirteen recreationally trained males (n=7) and females (n=6 ) served as subjects for the 
investigation. Subject descriptive characteristics are shown in Table 1. Prior to
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participation, each subject completed a University Institutional Review Board (IRB) 
approved informed consent form. All female subjects were eumenorrheic and had not 
been using any form of hormonal contraception for at least six months prior to the study. 
Preliminary descriptive testing was performed without regard to the menstrual cycle. 
However, all extended exercise trials were performed during the follicular phase of the 
menstrual cycle (1-4 days post-menses). All subjects were asked to maintain their normal 
exercise and dietary habits between the two trials. Each exercise trial was completed at 
least one week apart for male subjects and no more than one menstrual cycle apart for 
female subjects.
Anthropometric Measurements 
Paragraph 8
Hydrostatic weighing, at estimated residual volume was used to determine body fat 
percent and fat free mass Subjects performed multiple underwater weight trials until 
three values within 100 grams were obtained. Net underwater weight was determined 
using an electric, calibrated scale (Exertech, Dresbach, MN). Body density was then 
used to determine body fat percent using the age and sex specific equations o f Lohman 
(1992).
Exercise Testing 
Paragraph 9
All subjects were asked to report to the Human Performance Laboratory after abstaining 
from calories, nicotine, and caffeine for twelve hours prior to testing. Graded exercise
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tests to volitional exhaustion, to determine maximal oxygen uptake (VOipeak) and 
ventilatory threshold (VT) were performed on two separate days using an electronically 
braked Cardgirus cycle ergometer (CE) (Cardgirus, Spain), and a Quinton Q65 treadmill 
(TM) (Quinton, Seattle, WA). The testing protocol for the CE consisted o f a ramped 
protocol progressing at 40 watts per minute until volitional exhaustion, or until a cadence 
o f 50 revolutions per minute (rpm) could not be maintained. The testing protocol for the 
TM consisted o f a speed set at 1.8 m s ^ with an increase in one percent grade every 30 
seconds. At a respiratory exchange ration (RER) greater than 1.0 the speed was increased 
0.23 m s"*, every 30 seconds until volitional exhaustion.
Paragraph 10
Expired gas data were continuously collected using a two-way mouthpiece (Hans 
Rudolph, Inc., Kansas City, MO) and a ParvoMedics metabolic cart (ParvoMedics, Salt 
Lake City, UT). Prior to each expired gas collection calibration was performed using a 3- 
Liter calibration syringe (Hans Rudolph, Inc., Kansas City, MO), and a calibration gas 
mixture (16.0% O2, 4.0% CO2, N2 balance). Prior to each gas collection during the 
extended exercise trials, the metabolic system was calibrated as described above. Heart 
rate was continuously measured using a chest strap Polar Heart Rate monitor (Polar USA, 
Lake Success, NY). Three methods were used concurrently to determine the VT for the 
purpose o f determining workload for the CE and TM segments o f the extended exercise 
trials according to Gaskill et al. (2001)*'.
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Paragraph 11
After performing the graded treadmill test, subjects were asked to use the CardiOzcycie 
Exercise Dynamometer, upper body ergometer (UBE) (ErgometRx, St. Paul, MN) by 
simulating double or single poling during cross-country skiing. Subjects were asked to 
find a resistance equal to a rate of perceived exertion (RPE) of 9 to 10. Watts were 
monitored throughout the trial using Extend Software (SMI, St. Paul, MN).
Extended Exercise Trials 
Paragraph 12
Each subject performed two, 10-hour exercise trials in a double blind, random crossover 
design. Subjects received either CHO [20% maltodextrin (0.6g kg FFMT^-hr'^)] or an 
artificially sweetened placebo (PLA) drink of the same flavor, temperature and volume 
each hour.
Paragraph 13
In order to ensure similar muscle glycogen levels between trials, each subject was 
provided with a standardized meal plan, o f at least 5 g kg'^ CHO, and 1.2 g*kg'^ protein 
for the 24 hours before each trial. Although subjects were allowed to add to the meal 
plan prior to the first trial, the same dietary intake was duplicated prior to the second trial. 
Dietary analysis was conducted using Food Processor Nutrition Analysis Software 
(ESHA, Salem, OR). Subjects were also asked to refrain from any type of exercise for 24 
hours before each trial.
48
Paragraph 14
Subjects were asked to report to the Human Performance Lab at 0500, after abstaining 
from calories, nicotine, and caffeine for twelve hours prior to testing. An indwelling 
glucose sensor (Medtronic Minimed, Northridge, CA), with a flexible catheter was placed 
in the subcutaneous fat just above the right gluteus maximus, in order to continuously 
monitor blood glucose. One hour was set for equilibration of the glucose sensor. The 
OneTouch-Ultra glucometer (LifeScan, Milpitas, CA) was used to calibrate the glucose 
sensor immediately pre-exercise, pre-lunch, and post-exercise.
Paragraph 15
Subjects were then prompted to void their bladder and a pre-exercise weight was then 
obtained using a calibrated, digital scale (Befour Inc, Cedarburg, WI). A pre-exercise 
muscle biopsy was then obtained from the midsection o f the vastus lateralis. Subjects 
were placed in a supine position on a hospital bed, and the area was cleaned and draped 
with sterile dressings. Under local anesthetic a Bergstrom needle with modified suction 
was used to obtain the biopsy. Visible connective tissue and fat were dissected from the 
muscle tissue, and the sample was flash frozen in liquid nitrogen, and stored at -80°C for 
subsequent analysis.
Paragraph 16
A standardized breakfast (5 g*kg’  ̂CHO, and 1.2 g-kg'* protein) was provided for the 
subjects post-biopsy. Average time from breakfast to exercise was recorded and was 23
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and 22 minutes for the PLA and CHO trials, respectively. Exercise began after 
equilibration and calibration o f the glucose sensor.
Paragraph 17
The exercise protocol during the ten hours consisted of three different modes o f exercise 
performed for varying lengths of time, over an hour. Subjects began with UBE exercise 
at a self-selected speed and constant resistance for 9 minutes. A one-minute transition 
was allowed to the CE, where exercise was performed at 71 ±4% Tvent, and 44±4% 
V0 2 peak. Another one-minute transition was allowed to the TM, where exercise was 
performed at 71±3% Tvent, and 44±4% VOipeak for 20 minutes. At this time a ten-minute 
rest and feeding period (PLA or CHO of equal volume) occurred. A forty-minute lunch 
break was allowed between hours 5 and 6 , where a standardized lunch (5 g-kg"  ̂CHO, 
and 1.2 g kg"  ̂protein) was provided in place of the PLA/CHO feeding.
Paragraph 18
Heart rate was monitored using a chest strap Polar Heart Rate monitor (Polar USA, Lake 
Success, NY) during the last five minutes o f each hour of CE and TM portions of 
exercise. The five-minute average was recorded for PLA and CHO trials.
Paragraph 19
Immediately upon completion of the last hour, blood glucose was measured with the 
glucometer, and entered into the glucose sensor for calibration. Subjects were then 
instructed to void their bladder, and a post-exercise weight was obtained. Subjects were
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again placed in a supine position on the hospital bed and a second muscle biopsy was 
obtained from a second incision in the vastus lateralis, approximately 2 cm proximal to 
the initial biopsy site on the same leg. The muscle sample was collected and stored in the 
same manner as the initial muscle biopsy.
Metabolic Data 
Paragraph 20
Expired gases were collected during the initial five minutes on the CE to ensure that the 
appropriate workload [VO2 (L*min‘ )̂] was prescribed. After this time expired gases were 
collected during the last five minutes o f the TM segment o f the trial during hours 1 ,3 ,5 , 
6 , 8 , and 1 0 .
Whole Body Substrate Utilization 
Paragraph 21
Whole body substrate utilization was calculated from the TM segment of exercise using 
steady state VO2 and VCO2 data. The last 2.5 minutes o f expired gas data collected on 
the TM was averaged to determine VO2, VCO2, fat oxidation (pimol kg"  ̂min"\ pmol kg 
FFM’^-min'*) and CHO oxidation (pmol*kg''*min'^ pmol-kg FFM'^-min'^) ^ . Values 
were averaged for hours 1, 3, and 5 for AM and hours 6 , 8 , and 10 for PM estimates of 
whole body substrate oxidation.
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Muscle Glycogen Assay 
Paragraph 22
Muscle glycogen was analyzed using a spectrophotometric method (Infinity glucose 
reagent, Thermo Electron, Melbourne, Australia) after tissue preparation. Samples were 
weighed upon removal from a —80“C freezer. Samples were placed in lOOOpL, 1 N HCl 
solution and homogenized using a manual mortar and pestle tissue grinder. Once 
homogenized, samples were incubated at 95.6°C for three hours. After the incubation, 
500pL, 1 N NaOH was added to 500pL of boiled tissue sample to normalize pH.
Samples were analyzed in triplicate, after pipetting 40 mL of sample into ImL of the 
Infinity glucose reagent and incubating at room temperature for 15 minutes, using a 
spectrophotometer (Spectronic 402, Milton Roy, Rochester, NY), against glycogen and 
glucose controls. Muscle glycogenolysis was expressed in mmol kg"  ̂wet wt-hr"^ of 
muscle.
Statistical Procedures 
Paragraph 23
Descriptive data were expressed in M eaniSD. All descriptive data were analyzed across 
sex using an independent 2-tailed t-test. All other dependent variables were compared 
using a series o f mixed design ANOVA with repeated measures (Abacus Concepts, Inc, 
Berkley, CA). The level o f significance for the experiment was set at an overall alpha of
0.05.
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Results
Descriptive Data.
Paragraph 24
Comparative baseline descriptive data are summarized in Table 1. Males were heavier, 
with a lower percent body fat, higher FFM, and a higher absolute (L-min'^) and relative 
(ml kg'^*min ^ ml kg FFM^ min"^) V0 2 peak and absolute VT (L min‘ )̂. When values for 
VT were expressed relative to body mass, FFM and relative to peak oxygen consumption 
(%V0 2 peak) there were no significant differences between sexes.
Exercise Descriptives.
Paragraph 25
The workload intensities for VT and 70% VT are summarized in Table 2. There were no 
differences between males or females in the exercise intensities in either mode of 
exercise when expressed relative to VT. Conversely, when expressed relative to V0 2 peak, 
exercise was significantly higher for the females during the treadmill exercise. However, 
males performed exercise at a significantly higher absolute workload (watts) on the cycle 
ergometer than did females.
Paragraph 26
Heart rate (HR) and RPE data are summarized in Table 3. There were no differences 
between males and females in either HR or RPE for either trial. Slight increases were
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seen in RPE for the PLA trial compared to the CHO trial, but values were not statistically 
significant.
Blood Glucose 
Paragraph 27
Blood Glucose demonstrated no statistically significant difference between the sexes 
(Figure 1). Values for blood glucose were significantly higher for the CHO trial 
compared to the PLA trial for both sexes. There was a time x trial interaction that was 
statistically significant demonstrating decreased blood glucose across time in both CHO 
and PLA trials.
Substrate Oxidation 
Paragraph 28
Substrate oxidation derived from expired gases and metabolic equations are summarized 
in Table 4. There were no differences in calculated fat oxidation when values are 
expressed relative to FFM. Total energy expenditure was higher in males across all times 
and trials. There was also a statistically significant difference CHO oxidation during the 
PLA trial, demonstrating a higher rate o f CHO oxidation in females.
Whole Body Substrate Oxidation 
Paragraph 29
Whole body carbohydrate oxidation (expressed relative to total body weight and to FFM) 
demonstrated a significant sex x trial interaction. Values for CHO oxidation were
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significantly higher during the CHO trial compared to the PLA trial for both males and 
females. There was no significant difference between the males and females during the 
CHO trial. However, females maintained a significantly higher rate o f whole body CHO 
oxidation during the PLA trial compared to the males (Figures 2a,b). The time x trial 
interaction was also statistically significant. Hours 1-5 and 6-10 demonstrated 
significantly higher rates o f CHO oxidation values for the CHO trial compared to the 
PLA. In addition, CHO oxidation demonstrated a significant decrease during hours 6-10 
in the PLA trial. Although not statistically significant, the CHO trial showed a trend 
towards lower CHO oxidation through hours 6-10 (p=0.065) (Figure 2a,b).
Paragraph 30
Whole body fat oxidation (expressed relative to total body weight and to FFM) 
demonstrated no sex specific significant interactions (Figure 3a,b). Values for fat 
oxidation were significantly higher for the PLA trial compared to the CHO trial for both 
sexes. The time x trial interaction was statistically significant demonstrating increased 
fat oxidation in hours 6-10, compared to hours 1-5 in both trials. In addition, fat 
oxidation was maintained at higher rates during the PLA trial compared to the CHO trial 
in hours 1-5 and 6-10 (Figure 3a,b).
Glycogen 
Paragraph 31
For the measure o f muscle glycogen, there was no significant effect o f sex. However, the 
trial X time interaction indicated a significant decrease in muscle glycogen for both CHO
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and PLA trials. In addition, pre-exercise glycogen concentration was slightly but 
significantly higher for the PLA trial. In contrast, the post exercise glycogen 
concentration was significantly lower for the PLA trial compared to CHO (Figure 4).
Paragraph 32
When glycogen depletion was expressed in mmol kg'* wet wt hr \  there were no 
significant differences between the males and females. However, the main effect for trial 
demonstrated a significantly higher (78%) rate o f glycogenolysis for the PLA trial 
compared to the CHO (Figure 5).
Discussion
Paragraph 33
The purpose o f this investigation was to determine the effects of regular CHO feedings 
on whole body substrate oxidation and muscle glycogenolysis in recreationally active 
males and females during long duration, low-intensity, intermittent exercise. The notable 
results from this study demonstrated no significant sex specific differences in whole body 
substrate oxidation when values were expressed relative to body mass or FFM. These 
results are in contrast to Horton et al. (1998) who demonstrated that females oxidize a 
higher relative amotmt o f fat in comparison to males. However, these results are similar 
to the data of Riddell et al. (2003) who demonstrated a diminished effect o f sex when 
subjects were tested in the fed vs. fasted state. Interestingly, during the PLA trial females 
demonstrated a significantly higher rate o f CHO oxidation compared to males.
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Paragraph 34
In order to standardize exercise intensities, past researchers have matched subjects based 
on background exercise habits, competitive history, and V0 2 peak̂ ’ 19,23,28,29 Exercise 
intensity in the present study was expressed relative to VT in order to ensure similar 
workloads between sexes. Although females exercised at a significantly higher workload 
for the treadmill when expressed as a percent V0 2 peak, there was no difference in the 
percentage o f VT between the sexes. This ensures similar intensities for both modes of 
exercise between males and females.
Paragraph 35
In a study performed by Zderic et al. (2001) it was demonstrated that across the menstrual 
cycle there were differences in substrate oxidation. The results from this study 
demonstrated no differences in glucose kinetics, CHO and fat oxidation at low intensities. 
As the intensity o f exercise increased, Ra and Rd, along with CHO oxidation were lower 
in the luteal phase. Because of these findings all of the female subjects in the present 
study were eumenorrheic and tested in the follicular phase (1-4 days post menses) in 
order to ensure low levels o f circulating estrogen and progesterone.
Paragraph 36
Previous research has demonstrated that females display lower RER compared to males 
during exercise at the same percent V0 2 peak. Moreover, some research has demonstrated 
that females use less glycogen and have lower blood glucose concentrations at the end of 
exercise at intensities relative to V0 2 peak Levels o f estrogen and progesterone
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may have an impact on the source of CHO in females during exercise Ruby et al.
(2002) has also suggested that females may rely more heavily on blood glucose as a CHO 
source for energy during submaximal exercise. This has also been suggested by 
Friedlander et al. (1998) in a study that trained males and females to determine changes 
in substrate oxidation at the same absolute and relative exercise intensities. However, in 
the present study, blood glucose was not significantly different across trial or between the 
sexes. This further suggests that static measures o f blood glucose cannot adequately 
represent the complex patterns of glucose kinetics resulting from hepatic and gut Ra as 
well as muscle glucose uptake and oxidation.
Paragraph 37
In this investigation higher rates o f CHO oxidation were observed for both males and 
females during the CHO trial. These findings are consistent with findings from past 
research. When exogenous CHO is provided during endurance exercise a higher RER, 
and therefore higher rates o f CHO oxidation have been consistently demonstrated 
However, during the CHO trial, there were no differences between the sexes. In 
contrast, during the PLA trial, fat oxidation increased late in the trial. Moreover, during 
this trial, females displayed higher rates o f whole body CHO oxidation compared to 
males. Although females exercised at a higher % VOzpeak than males, the values for % 
VT were not statistically significant (Table 2), ensuring similar workloads for both sexes. 
Therefore, these results are in opposition with past research However, a
possible explanation for this may be related to the design of this exercise trial. Although 
past research has suggested that estradiol may exert subtle metabolic effects on substrate
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metabolism during submaximal exercise, these variations may be overridden by the stress 
associated with the present exercise. The subjects in this study were trained subjects, and 
did not perform exercise completely fasted. This exercise trial was also performed at an 
intensity below 50% VOzpeak, and for a period of 10 hours, a much longer duration than 
has been studied in the past. Therefore, the influences o f the exercise protocol may have 
a more influential effect on substrate metabolism compared to the small effects associated 
with the reproductive hormonal milieu
Paragraph 38
It has been demonstrated that CHO feedings administered at a high rate (1.0-1.7 g*min'^) 
can completely suppress liver glycogenolysis, but there is conflicting data regarding the 
effects on muscle glycogenolysis In the present study the rates of muscle
glycogenolysis were approximately 78% higher for the PLA trial. However, there were 
no differences between the sexes. This data is supported by the recent findings of 
Zehnder et al. (2005) where subjects cycled for three hours at 50% VOipeak Muscle 
biopsy data indicated a main effect for time, showing a significant reduction in muscle 
glycogen and intramuscular triglyceride (IMTG) utilization. However, there was no sex 
specific difference in muscle substrate oxidation. This investigation also demonstrated a 
dramatic muscle glycogen “sparing” effect for both sexes, when CHO was provided at a 
rate o f approximately 37 g hour *. Interestingly, this rate o f feeding is lower than the 
optimal rates suggested by Jeukendrup et al. (2000) to maximize the rate of exogenous 
CHO.
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Paragraph 39
In conclusion, the results from this study indicate that females and males exhibit similar 
patterns o f whole body and muscle glycogen utilization when fed CHO during extended 
exercise. These results suggest that future research should further evaluate the potential 
o f muscle glycogen sparing during long duration exercise and/or occupational settings 
when exogenous CHO is provided on a regular basis.
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6 1
Table 1. Subject Descriptive Characteristics (N=13)
Variable Males (n=7) Females (n=6 )
Age (yr) 26.1± 6.1 2 2 .8± 3.1
Height (cm) 180.4± 9.2 171.6± 8.9
Body Mass (kg) 77.0± 10.1 62.6± 4.7*
Percent Body Fat (%) 9.8± 4.0 14.2± 2.5*
Fat Free Mass (FFM) (kg) 69.2± 7.5 53.7± 4.9*
Fat Mass (kg) 7.8± 3.9 8 .8± 1.4
VOipeak Treadmill 
L/min 4.5± 0 .6 3.1=t 0.3*
ml/kg/min 58.3± 5.5 49.7± 4.0*
ml/kg FFM/min 64.7± 5.9 58.0± 4.9*
% VOzpeak at VT Treadmill 60.3± 4.3 65.4± 7.9
VOzpeak Cycle 
L/min 4.3± 0.5 2 .8± 0.5*
ml/kg/min 56.2± 7.3 45.1± 6.9*
ml/kg FFM/min 62.2± 7.1 52.6± 8 .1*
% VOzpeak at VT Cycle 58.4± 4.2 64.4± 10.5
Values are expressed Mean±SD. VOipeak, peak O2 uptake, VT, ventilatory threshold, 
FFM, fat free mass. *p < 0.05 vs. males.
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Table 2. Exercise Intensities (N=13)
70% VT
Maies (n=7) Females (n=6 )
% VT Treadmill 69.4± 1.9 71.9± 4.1
%VT Cycle 72.3± 4.2 70.5± 3.8
% VOipeak Treadmill 41.8± 2.4 46.8± 3.9*
% VOipeak Cycle 42.1± 1-6 45.1± 5.8
Treadmill % Grade 5.4± 1.7 4.7± 1.9
Cycle Workload (Watts) 103.6± 23.8 70.5± 19.0*
Values are expressed Mean±SD. *p < 0.05 vs. males.
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Carbohydrate Placebo
Variable
Males
(n=7)
Females
(n=6 )
Males
(n=7)
Females
(n=6 )
Heart Rate Cycle 
Ergometer 116±8.3 115±8.8 121Ü0.7 115±8.8
Heart Rate Treadmill 116±8.7 130±8.5 1 2 1 ± 1 0 . 0 132±11.4
RPE 1 0 ± l -8 12±1.3 l l i l . 9 1 2 ± 1 .1
Values are expressed Mean±SD.
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TabJ^^ubstrjteOrjdjtioin^îl^^
C arbohydrate____________________________________________ Placebo
________ Males (n=7)_______________ Females (b=6) M ales (n~7)_______________Females (n=6)______
V ariable AM PM AM PM  AM PM  AM PM
R E R  0.91 ±0.02 0.90±0.03 0.92±0.03 0.90i0.04 0.86±0.04 0.82±0.05 0.88±0.04 0.85±0.04*
kkcal/m in 8.9±1.1 9.1±1.1 7.0±1.1* 7.1±1.2» 9.0±0.9 9.0±1.1 7.1±1.2* 7.1±1.2*
C H O  O xidation (umol/kg FFM/miD) 134.3±11.1 I28.5±10.6 141.9±16.2 131.6±26.4 101.7±I6.4 76.4±17.9 1!5.5±17.3 97.7±12.4*
Fat Oxidation (nm ol/kg FFM /m in) 4 7±1,4 5.3±2.1 4.3±1.7 5.4j:2.5 7.6±2.3 9.7±2.3 6.5±1.7 8.2±1.8
Values arc expressed Mean±SD. *p<0.05 vs. Males
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Figure 2a. Whole body carbohydrate oxidation (|a.mol-kg‘^-min‘ )̂ for the two exercise 
trials. *p<0.05 vs. AM for PLA (trial x time interaction), "f p<0.05 vs. Males for 
PLA (trial x sex interaction).
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Figure 2b. Whole body carbohydrate oxidation ((amol-kg FFNT^-min'*) for the two
exercise trials. *p<0.05 vs. AM for PLA (trial x time interaction), t  p<0.05 vs. 
Males for PLA (trial x sex interaction).
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Figure 3a. Fat Oxidation (pimol-kg"^ min"^) for the two exercise trials. *p<0.05 vs. AM 
for PLA (trial x time interaction).
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Informed Consent Form
Effects of carbohydrate feedings on blood glucose and muscle glycogen during
extended exercise
Principal Investigator: Brent C. Ruby, Ph D.
Location: Human Performance Laboratory
McGill Hall #121 
The University of Montana 
Missoula, MX 59812 
(406) 243-2117/(406) 243-4780
Purpose
The purpose o f this project is to determine the effects of high carbohydrate food/drink 
sources on blood glucose, and changes in muscle glycogen during extended exercise. 
The information collected in this study will help determine if  the effects o f extra 
carbohydrate consumption will alter work performance and minimize fatigue.
As a participant in this study you will complete the following assessments. 1) a pre­
screening assessment which involves a health/exercise history questionnaire (Par-Q), 2) a 
measure o f percent body fat obtained using a underwater weighing, 3) a maximal 
treadmill test and maximal cycle ergometer test to measure aerobic fitness levels, 4) two 
ten-hour work/rest sessions involving cycling, treadmill walking and arm exercise, 5) the 
completion o f a mood state survey (the Profile of Mood States) at six times during the 
study, 5) collection o f expired gases to determine fuel use during the 10-hour work/rest 
session, 6 ) consumption of one of two different types o f liquid carbohydrate every hour 
o f exercise, 7) finger-stick blood samples every two hours to determine blood glucose 
during activity, 8 ) two muscle biopsies to be collected a) early in the morning before the 
exercise session begins, and b) late in the afternoon after the exercise session is 
completed.
Body Fat Measurement -  Underwater Weighing:
This test session will require that subjects do not eat for a minimal o f 3 hours 
prior to the testing. Prior to the test, body weight will be recorded in your 
bathing suit. Subjects will then be asked to complete between 3 —6 
underwater weighing procedures. The underwater weight requires that 
subjects are submersed in our weighting tank (similar to a hot tub) and that 
they maximally exhale as much air as possible while underwater. The 
underwater weight will be recorded within 2-4 seconds and then subjects will 
be signaled to surface. This procedure will be repeated until three 
measurements have been obtained that are within 100 grams of each other. A 
nose clip will be provided upon request. This test will take approximately 30 
minutes.
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Maximal Exercise Test — Treadmill:
This test will consist o f walking and running on a motorized treadmill to a 
maximal effort. The speed and grade of the treadmill will progress to fatigue. 
Subjects will be encouraged to continue to walk/run until exhaustion. During 
the entire testing session on the treadmill, subjects will wear a nose clip and 
headgear that will support a mouthpiece. This will allow us to measure the 
amount o f oxygen the body uses during the exercise. Heart rate will be 
measured using an elastic chest strap that is worn on the skin under your shirt 
around your chest. This test will take approximately 45 minutes to 1-hour. 
Subjects will be asked to fast for approximately 3 hours prior to this test.
Maximal Exercise Test — Cycle:
This test will consist o f riding on a laboratory exercise cycle to maximal 
effort. The resistance o f the cycle will increase each minute and will progress 
to fatigue. Subjects will be encouraged to continue to ride until exhaustion. 
During this test the subjects will wear a nose clip and headgear that will 
support a mouthpiece. This will allow us to measure the amount o f oxygen 
that the body uses during this exercise. Heart rate will be measured using an 
elastic chest strap that is worn on the skin under your shirt around your chest. 
This test will take approximately 45 minutes to 1 hour. Subjects will be asked 
to fast for approximately three hours prior to this test.
Maximal Exercise Test — Arm ergometer:
This test will consist o f using an upper body machine with ropes and pulleys 
to simulate cross-country skiing to maximal effort. The resistance o f the 
machine will increase each minute and will progress to fatigue. Subjects will 
be encouraged to continue to continue until exhaustion. During this test the 
subjects will wear a nose clip and headgear that will support a mouthpiece. 
This will allow us to measure the amount o f oxygen that the body uses during 
this exercise. Heart rate will be measured using an elastic chest strap that is 
worn on the skin under your shirt around your chest. This test will take 
approximately 30-45 minutes. Subjects will be asked to fast for 
approximately three hours prior to this test.
10-hour Exercise/Rest Session:
The order o f these sessions will be randomized and blinded to the study 
participants. Subjects will be asked to report to the laboratory after a 12 hour 
fast, at approximately 6:00 AM. Each hour of exercise will consist o f the 
three activities explained above. The first 10 minutes will be self selected 
exercise using the upper body machine, the next 2 0  minutes will be performed 
on the cycle at a predetermined intensity, and the next 2 0  minutes will be 
walking on the treadmill at a predetermined intensity. Every other hour while 
walking on the treadmill expired gases will be collected for approximately 6
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minutes using the nose clip, headgear, and mouthpiece mentioned above. The 
last 10  minutes o f the hour will allow for rest and feeding.
Muscle Biopsies:
A total o f four muscle biopsies will be obtained jfrom your front thigh muscle 
(vastus lateralis -  approximately 6  inches up from the kneecap on the lateral 
side o f your thigh). The muscle biopsy procedure requires that the sight be 
sterilized. After the sight is cleaned, a small amount o f lidocaine will be 
injected just under the skin surface. Additional small amounts o f lidocaine 
Avill be injected around a small 1-inch area around the sight on the leg. After 
the area is treated with the lidocaine (approximately 5 ml, lOmg/ml), a small 
incision (approximately 1/4 inch long) will be made through the skin and to a 
depth o f approximately 3/4 inches. The biopsy needle will then be inserted 
through the incision and the sample obtained. After the sample is obtained, 
the site v^ill be cleaned and closed with steri-strips and wrapped with an ace 
bandage. A flexible ice pack will then be placed on the site for 10 minutes. 
The biopsy samples will be obtained a) prior to the 10-hour exercise/rest 
session, and b) immediately after the 1 0 -hour exercise/rest session (on the 
same leg but approximately 2 inches above the initial sample). This will be 
repeated for the second trial using the opposite
leg. The muscle biopsies will only be used to evaluate alterations in muscle 
carbohydrate stores in response to physical activity. Latex free bandages will 
be provided if  subjects have a known allergy to latex.
Body Weight:
Your nude body weight will be measured using a digital scale prior to, after 5-hours, and 
immediately following each 10-hour exercise/rest session. All measures will be done in 
private.
Surveys:
You will be asked to complete a 60-question survey that has been developed to assess 
you opinions regarding your current mental state prior to, at the mid point and 
immediately following the each 10-hour exercise/rest session. You are asked to provide 
an accurate and truthful response to each question.
Supplemental Carbohydrate Beverage:
During each 10-hour exercise/rest session, you will be given one o f two different 
carbohydrate containing beverages. You will be asked to drink a predetermined amount 
(200 ml, approximately 6.7 oz, just less than 1 cup) o f the solution at the top o f each hour 
and throughout the entire 10-hour session. You will also be provided with a small 
standardized lunch at the 5-hour mid point.
F inger blood samples to determ ine blood glucose during activities.
During each 10-hour exercise session, periodic finger stick blood samples will be 
collected prior to and following each hour o f exercise. These samples are being collected 
to evaluate changes in blood sugar throughout each exercise session.
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Risks and Discomfort
1. Mild discomfort may result during and after the exercise. These discomforts include 
shortness o f breath, tired or sore legs, nausea and possibility o f vomiting,
2. Muscle soreness after the tests may occur as a result o f the exercise, but should not 
persist.
3. Certain changes in body function take place when any person exercises. Some of 
these changes are normal and others are abnormal. Abnormal changes may occur in 
blood pressures, heart rate, heart rhythm or extreme shortness o f breath. Very rare 
instances o f heart attack have occurred, as with other moderately strenuous exercise 
activities. Every effort will be made to minimize possible problems by the 
preliminary evaluation and constant surveillance during testing. A trained CPR 
technician will be on hand at all times and the laboratory has standard emergency 
procedures should any potential problems arise.
4. You will be informed o f any new findings that may affect your decision to remain in 
the study.
5. The muscle biopsy and blood sampling techniques may cause some local and 
temporary discomfort. It is normal to have the sensation of a deep tissue bruise 
around the site of the muscle biopsy. This pain should be manageable and not above 
the pain associated from a “charlie horse” type bruise.
6 . There is a minor risk o f infection associated with blood sampling and the muscle 
biopsy. Should you notice unusual redness, swelling or drainage at the biopsy 
incision site, you should seek medical attention and then notify Brent Ruby, study 
director.
7. There are minimal risks associated with the use of lidocaine (the local anesthetic).
The risk o f a reaction to the lidocaine is extremely low (approximately 1/1,000,000). 
However to minimize this risk we will use no more than 5-7 ml of a 10% hdocaine 
solution per biopsy.
8 . During any of the exercise tests should symptoms, such as chest discomfort, unusual 
shortness o f breath or other abnormal findings develop, the exercise physiologist 
conducting the research will terminate the test. Guidelines by the American College 
o f Sports Medicine will be followed to determine when a test should be stopped.
Benefits of Participating in This Study
1. There is no promise that you will receive any benefit outside of the financial payment 
as a result o f taking part in this study.
2. The information from these tests will provide you with an accurate assessment o f you 
aerobic fitness and body composition that can be compared with norms for your age 
and sport but may be of little benefit to your understanding of your personal fitness. 
There are no other direct benefits to the participants in the study.
3. Upon completion o f the preliminary tests (body fat, treadmill, cycle and arm 
ergometer max tests), you will be paid $25. Upon completion o f the first 10-hour 
exercise/rest session, you will be paid another $75. Upon completion of the second 
10-hour session, you will be paid another $100. Therefore, upon completion o f the 
entire study, you will be paid a total o f $200. If  you decide to withdraw at any time, 
you will be compensated for the test sessions you have completed or initiated.
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Confidentiality
All results will be kept in strict confidence among the subject involved and the Principal 
Investigators and other Co-Investigators. During the entire period of data collection, 
subject records will be kept within the Human Performance Laboratory and will be 
locked under the direction of the Principal Investigator.
Compensation for Injury
Although we believe that the risk of taking part in this study is minimal, the following 
liability statement is required in all University of Montana consent forms. In the event 
that you are injured as a result o f  this research you should individually seek appropriate 
medical treatment. I f  the injury is caused by negligence o f  the University or any o f  its 
employees, you may be entitled to reimbursement pursuant to the Comprehensive State 
Insurance Plan established by the Department o f  Administration under the authority o f  
M.C.A., Title 2, Chapter 9. In the event o f  a claim fo r  such injury, further information 
may be obtainedfrom the University's Claim representative or University Legal Counsel.
Voluntary Participation and Withdrawal
It is important that you realize that you are free to withdraw from the study at any time. 
As mentioned above, even if  you decide to drop out o f the study, you will receive full 
compensation for all the test sessions you complete or initiate.
A copy o f this consent form will be provided for you. In addition, the data collected 
during this study will be done at no cost to you.
Statement of Consent
I have read the above statements and understand the risks involved with this study. I 
authorize Brent C. Ruby and such assistants that he may designate, to administer and 
conduct the testing as safely as possible with a minimal amount o f discomfort. If I have 
additional questions, I may contact Brent C. Ruby at home (406) 542-2513 or at the 
Human Performance Laboratory (406) 243-2117.
Participant (print)
Signature  Date
Permanent Address _____________________________________
Investigator/Witness S ignature_____________________________________
(print)
Investigator/Witness Signature _________________________________ Date
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Table 1. Subject Descriptive Characteristics (N=7)
Variable Mean± SD
Age (yr) 26.1± 6,1
Height (cm) 180.4± 9.2
Body Weight (kg) 77.0± 10.1
Percent Body Fat (%) 9.8± 4.0
Fat Free Mass (FFM) (kg) 69.2± 7.5
Fat Mass (kg) 7.8± 3.9
VOzpeak Treadmill (ml/kg/min) 58.3± 5.5
Percent VOzpeak at Tvent Treadmill (%) 60.3± 4.3
VOipeak Cycle (ml/kg/min) 56.2± 7.3
Percent VOipeak at Tvent Cycle (%) 58.4± 4.2
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Table 2. Ventilatory Characteristics During Exercise
Variable Mean± SD
V0 2 peak Treadmill (L/min) 4.5± 0 .6
VOzpeak Treadmill (ml/kg/min) 58.3± 5.5
Tvent Treadmill (L/min) 2.69± 0.3
Tvent Treadmill (ml/kg/min) 35.2± 4.1
70% Tvent Treadmill (L/min) 1.9± 0 .2
70% Tvent Treadmill (ml/kg/min) 24.6± 2 .8
VOzpeak Cycle (L/min) 4.3± 0.5
VOzpeak Cycle (ml/kg/min) 56.2± 7.3
Tvent Cycle (L/min) 2.5± 0.4
Tvent Cycle (ml/kg/min) 32.8± 4.9
70%Tvent Cycle (L/min) l-8± 0.3
70% Tvent Cycle (ml/kg/min) 23.0± 3.5
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Table 3. Blood Glucose 
Data
Pre Mid Post
Variable Mean ±SD Mean ±SD Mean ±SD
Glucose Sensor PLA (mM) 
Glucose Sensor CHO (mM)
7.0 ±2.0 
7.9 ±1.0
6.2 ±0.9* 
7.1 ±2.1*
5.2 ±0.7* 
6.4 ±2.0*
Glucometer PLA (mM) 
Glucometer CHO (mM)
7.6 ±1.2 
7.3 ±1.3
5.8 ±0.4* 
6.7 ±0.9*
5.0 ±0.6* 
5.4 ±0.4*
* Statistically significant fi-om Pre, main effect for time 
(p<0.05)
(N=6 ) for Glucose Sensor 
(N=7) for Glucometer
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Figure 1 . Body Weight (kg) pre and post in each exercise trial. tp<0.05 vs. Pre.
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Figure 3. Heart Rate (bpm) for the Cycle Ergometer. *p<0.05 vs. CHO trial.
89
1 3 5
130
'e  125
a.o
V% 120 
cc
L .
10(Ü 115
110
105
PLA
CHO
1 2 3 4 5 6 7 8 9  10
Time (Hour)
Figure 4. Heart Rate (bpm) for the Treadmill. *p<0.05 vs. CHO trial.
90
8.5
8
PLA
CHO
z
ESw#
01Mou
3
5
o
7.5
7  H
5
5.5
5
4.5
Pr e 4  5 Lunch 6 7
Time (Hour)
8 10
Figure 5. Blood Glucose (mM) from the Indwelling Glucose Sensor. *p<0.05 vs. 
CHO trial.
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Figure 6 . Blood Glucose (mM) from the Glucometer.
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Figure 7. Rate of Perceived Exertion (RPE). *p<0.05 vs. CHO trial.
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Figure 8 . Oxygen Demand, VO2 (L min ') during Treadmill Exercise. *p<0.05 vs. 
CHO triaL
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Figure 9. Respiratory Exchange Ratio (R£R) from Expired Gases during Treadmill 
Exercise. *p<0.05 vs. CHO trial.
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Figure 10. Carbohydrate Oxidation (g min^) during Treadmill Exercise. *p<0.05 
vs. CHO trial.
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Figure 11. Total Carbohydrate Oxidation (g) during Treadmill Exercise. *p<0.05 
vs. CHO trial.
97
0.85
0.75
I  0.65
oi
c o
(D
0.55
^  0.45
X
O
% 0.35 u.
0.25
0.15
4 5 6
Time (Hour)
8
PLA
CHO
10
Figure 12. Fat Oxidation (g*min" )̂ during Treadmill Exercise. *p<0.05 vs. CHO 
trial.
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Figure 13. Total Fat Oxidation (g) during Treadmill Exercise. *p<0.05 vs. CHO 
trial.
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Figure 15. Total Urine Void (L).
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Figure 16. Urinary Nitrogen (mg*dL *).
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Figure 17. Muscle Glycogen (mmol* kg wet weight *). tp<0.05 vs. Pre. *p<0,05 vs. 
CHO tria l
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Appendix III
104
10 Hour Male Study - Stephanie Harger
Baseline Testing Baseline Testing
Subiect # Age Height (cm)
Weight
(kg)
% Body 
Fat
TM
V02max TM V02vt
TM 70% 
V02vt
1 29 176.5 71.2 5.9 3.95 2.6 1.82
2 23 170.2 82.3 14.3 4.14 2.43 1.7
3 20 167.6 62.5 6.2 4.15 2.48 1.73
4 37 185.4 77.8 8.9 4.96 2.94 2.06
5 30 185.4 85.6 16.3 5.14 3.25 2.27
6 23 193 91.1 9.3 5.16 2.7 1.89
7 21 185 68.7 7.8 3.83 2.41 1.69
A v e r a g e 2 6 1 8 0 .4 7 7 .0 9 .8 4 .5 2 .7 1 .9
S D 6 .1 9 .2 1 0 .1 4 .0 0 .6 0 .3 0 -2
S td
E rro r 2 .3 3 .5 3 .8 1 .5 0 .2 0 .1 0 .1
Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Subiect # Trial
Pre Weight 
(kg)
Post
Weight
(kg) ml drink
USE 
Watts 1
USE 
Watts 2
UBE 
Watts 3
1 A 69.5 69.3 200 23.22 19.33 18.11
2 A 83.1 82.6 212 36.7 41.8 40.3
3 A 62.6 61.1 176 14.3 14 18
4 A 79.8 79.0 213 52.9 55 56.6
5 A 82.7 81.5 215 17.7 17.4 20.3
6 A 91.8 91.4 248 14.1 15 16.3
7 A 73 71.2 190 31.0 32.44 30.22
A v e r a g e 7 7 .5 7 6 .6 2 0 7 .7 2 7 .1 2 7 -9 2 8 .5
S D 9 .8 1 0 .1 2 2 .7 1 4 .2 1 5 -8 15 .1
S td
E rro r 3 .7 3 .8 8 .6 5 .4 6 .0 5 .7
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
Subiect# Trial
Pre Weight 
(kg)
Post
Weight
(kg) ml drink
USE 
Watts 1
USE 
Watts 2
UBE 
Watts 3
1 B 71.4 69.8 200 15.4 12 18.6
2 B 83.3 82.7 212 32.1 32.4 31.7
3 B 62.5 61 176 16.2 15.9 15.6
4 B 80.4 79.1 213 48.4 53.4 53.2
5 B 86.2 84.2 215 15.9 18 9 17.7
6 B 92.4 91.9 248 12.4 12.2 13.4
7 B 7 1 3 71.5 190 22 26.2 25.89
Average 7 8 .2 7 7 .2 2 0 7 .7 2 3 -2 2 4 .4 2 5 .2
SD 1 0 .3 1 0 .4 2 2 .7 1 2 -9 1 4 -8 1 3 .9
Std
Error 3 .9 3 .9 8 .6 4 .9 5 .6 5 .3
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B a s e l in e  T e s t in g B a s e l in e  T e s t in g B a s e l in e  T e s t in g
TM VT % 
grade
TM 70% 
grade
CYCLE
V02max
CYCLE
V02vt
CYCLE
70%
V02vt
CYCLE VT 
Watts
CYCLE 
70% Watts
12 4.5 3.81 2.33 1.63 190 95
10 3 3.53 2 1.4 160 60
15 7.5 4.01 2.39 1.68 210 110
14 7 4.36 2.24 1.57 190 110
14 6.5 4.84 2.79 1.95 230 95
10 4 5.05 3.28 2.3 280 120
13 5 4.43 2.53 1.77 280 135
1 3 5 .4 4 .3 2 .5 1 .8 2 2 0 1 0 4
2 .0 1 .7 0 .5 0 .4 0 .3 4 6 .2 2 3 .8
0 .8 0 .6 0 .2 0 .2 0 .1 1 7 .5 9 .0
Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
UBE Watts UBE UBE UBE UBE UBE Watts UBE Watts SS HR
4 Watts 5 Watts 6 Watts 7 Watts 8 9 10 Cvc 1
13.56 14.67 15.78 15.78 17.22 14.44 13.25 117
40.2 39.8 36.3 37.4 36.1 34 33.2 123
18.55 21.77 18.5 20.1 18.77 19.2 24.1 128
57 57 56.4 57.4 56.9 57.2 58.7 117
18.2 16.9 21.6 17.8 17.5 17 17.7 120
16 15.8 12.6 14.8 14.9 16 12.7 119
30 29.67 30.22 28.56 29 30.67 30.33 107
2 7 .6 2 7 .9 2 7 .3 2 7 .4 2 7 .2 2 6 .9 2 7 .1 1 1 8 .7
1 6 .0 1 5 .7 1 5 .2 1 5 .5 1 5 .2 1 5 .4 1 6 .0 6 .4
6 .0 5 .9 5 .8 5 .9 5 .7 5 .8 6 .1 2 .4
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
UBE Watts UBE UBE UBE UBE UBE Watts UBE Watts SS HR
4 Watts 5 Watts 6 Watts 7 Watts 8 9 10 Cycl
17.2 16.4 15.6 15.2 13 19.2 17.6 113
32.2 29.4 31.5 31.3 31 29.3 29.6 116
14.7 14.6 13.2 13.6 15.9 13.6 16.6 124
54.9 54.9 55.2 55.1 57.4 56.7 57.1 112
15.4 17.7 19.6 17.6 18.4 19.3 16.6 126
14.6 12.7 12.2 15.2 13.3 15.8 14.7 122
23.89 28.67 25 26 27.78 *29.11 28 111
2 4 .7 2 4 .9 2 4 .6 2 4 .9 2 5 .3 2 6 .1 2 5 .7 1 1 7 .7
1 4 .8 1 4 .8 1 5 .1 1 4 .9 1 5 .8 1 4 .8 1 5 .0 6 .2
5 .6 5 .6 5 .7 5 .6 6 .0 5 .6 5 .7 2 .3
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
S S  HR S S  HR S S  HR S S  HR S S  HR S S  HR S S  HR S S  HR S S  HR
Cyc2 Cyc3 Cyc4 Cyc5 Cyc 6 Cyc 7 Cyc 8 Cyc 9 Cyc 10
116 114 111 118 123 116 117 122 120
125 125 124 132 146 141 140 148 152
121 124 121 125 135 124 124 126 124
116 110 115 118 130 123 120 123 123
124 127 122 134 139 135 138 132 130
117 116 115 114 131 119 118 119 120
99 100 99 96 111 104 98 102 103
1 1 6 .9 1 1 6 .6 1 1 5 .3 1 1 9 .6 1 3 0 .7 1 2 3 .1 1 2 2 .1 1 2 4 .6 1 2 4 .6
8 .7 9 .7 8 .5 1 2 .8 1 1 .3 1 2 .2 1 4 .2 1 3 .9 1 4 .7
3 .3 3 .7 3 .2 4 .8 4 .3 4 .6 5 .4 5 .2 5 .5
Trial B Trial 8 Trial B Trial B Trial B Trial B Trial B Trial B Trial B
S S  HR S S  HR S S  HR S S  HR S S  HR S S  HR S S  HR S S  HR S S  HR
Cyc2 Cyc3 Cyc4 Cyc 5 Cyc 6 Cyc 7 Cyc 8 Cyc 9 Cyc 10
107 107 106 108 112 108 106 108 109
117 109 110 110 114 125 119 125 130
127 124 125 128 134 132 128 127 130
115 108 113 112 116 115 113 114 112
124 123 120 127 127 126 125 128 142
116 110 110 108 112 115 113 111 114
107 106 102 107 113 110 109 108 98
1 1 6 .1 1 1 2 .4 1 1 2 .3 1 1 4 .3 1 1 8 .3 1 1 8 .7 1 1 6 .1 1 1 7 .3 1 1 9 .3
7 .6 7 .7 7 .9 9 .2 8 .7 9 .0 8 .2 9 .1 1 5 .2
2 .9 2 .9 3 .0 3 .5 3 .3 3 .4 3 .1 3 .4 5 .7
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
S S  HR 
TM 1
S S  HR 
TM2
S S  HR 
TM3
S S  HR 
TM4
S S  HR 
TM5
S S  HR 
TM6
S S  HR 
TM7
S S  HR 
TM8
S S  HR 
TM9
129 115 119 117 125 124 123 122 125
130 122 120 117 125 137 136 138 137
128 124 119 117 122 129 121 123 125
120 118 117 121 123 133 126 122 126
120 124 121 124 129 133 133 137 136
119 115 111 110 110 127 121 115 109
100 95 94 98 98 105 92 114 113
1 2 0 .9 1 1 6 .1 1 1 4 .4 1 1 4 .9 1 1 8 .9 1 2 6 .9 1 2 1 .7 1 2 4 .4 1 2 4 .4
1 0 .3 1 0 .1 9 .6 8 .6 1 0 .9 1 0 .6 1 4 .3 9 .6 1 0 .5
3 .9 3 .8 3 .6 3 .2 4 .1 4 .0 5 .4 3 .6 4 .0
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
S S  HR 
TM 1
S S  HR 
TM2
S S  HR 
TM 3
S S  HR 
TM4
S S  HR 
TM 5
S S H R
TM6
S S  HR 
TM 7
S S  HR 
TM8
S S H R
TM9
114 108 110 110 111 116 111 114 117
118 117 115 107 109 115 117 117 118
132 120 119 119 122 130 125 124 121
115 115 117 118 117 119 116 117 115
130 127 126 126 127 127 130 133 135
108 107 104 101 110 108 106 110 110
114 103 101 101 104 112 105 103 104
1 1 8 .7 1 1 3 .9 1 1 3 .1 1 1 1 .7 1 1 4 .3 1 1 8 .1 1 1 5 .7 1 1 6 .9 1 1 7 .1
8 .9 8 .4 8 .7 9 .6 8 .1 7 .9 9 .3 9 .7 9 .7
3 .4 3 .2 3 .3 3 .6 3 .1 3 .0 3 .5 3 .6 3 .7
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Blood
Glucose Blood Blood Blood Blood Blood Blood Blood
SS HR Pre Glucose Glucose Glucose Glucose Glucose Glucose Glucose
TM 10 (mg/dL) 1 2 3 4 5 Lunch 6
122 152.67 103.17 97.08 81.25 80.83 97.00 130.60 109.50
144 139.33 118.17 106.25 90.42 82.50 82.00 88.50 84.50
126 99.33 89.75 96.25 105.67 111.50 113.92 127.50 122.92
128 154.67 136.08 124.83 111.75 102.67 100.00 104.40 106.00
144 143.00 118.83 114.17 111.67 101.58 96.67 98.00 110.42
118 64.67 57.50 63.42 87.42 107.17 108.50 118.80 100.25
105 148.67 108.75 109.83 134.67 138.58 130.50 138.33 111.58
1 2 6 .7 1 2 8 .9 1 0 4 .6 1 0 1 .7 1 0 3 .3 1 0 3 .5 1 0 4 .1 1 1 5 .2 1 0 6 .5
1 4 .0 3 4 .0 2 5 .3 1 9 .6 1 8 .4 1 9 .4 1 5 .4 1 8 .5 1 1 .9
5 .3 1 2 .8 9 .6 7 .4 7 .0 7 .3 5 .8 7 .0 4 .5
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
Blood
Glucose Blood Blood Blood Blood Blood Blood Blood
SS HR Pre Glucose Glucose Glucose Glucose Glucose Glucose Glucose
TM 10 (mg/dL) 1 2 3 4 5 Lunch 6
114 132.00 122.08 140.08 136.42 131.58 125.25 129.67 115.83
129 174.67 121.00 180.75 153.09 151.92 110.58 198.40 187.33
126 134.33 143.50 129.92 123.83 119.92 110.42 112.40 114.00
120 131.67 114.58 109.50 110.50 108.50 105.42 103.83 102.42
140 127.67 113.17 103.75 100.83 95.50 94.25 96.40 88.17
111 152.00 125.67 119.08 116.50 114.75 109.00 121.20 100.67
110 166.67 123.83 126.25 117.67 101.58 102.83 113.17 80.83
1 2 1 .4 1 4 5 .6 1 2 3 .4 1 2 9 .9 1 2 2 .7 1 1 7 .7 1 0 8 .3 1 2 5 .0 1 1 2 .8
1 1 .0 1 9 .0 1 0 .0 2 5 .6 1 7 .3 1 9 .2 9 .4 34 .1 3 5 .2
4 .1 7 .2 3 .8 9 .7 6 .6 7 .3 3 .6 1 2 .9 1 3 .3
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T rial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Blood
Glucose
7
Blood
Glucose
8
Blood
Glucose
9
Blood
Glucose
10
Blood
Glucose
Pre
(mM)
Blood
Glucose
1
Blood
Glucose
2
Blood
Glucose
3
Blood
Glucose
4
102.17 97.83 95.08 94.00 8.48 5.73 5.39 4.51 4.49
82.75 82.50 81.33 81.17 7.74 6.56 5.90 5.02 4.58
116.15 114.77 110.77 107.62 5.52 4.99 5.35 5.87 6.19
100.58 83.25 77.67 76.92 8.59 7.56 6.94 6.21 5.70
107.83 104.75 105.25 107.33 7.94 6.60 6.34 6.20 5.64
111.08 105.75 95.17 97.75 3.59 3.19 3.52 4.86 5.95
119.08 117.42 115.17 109.17 8.26 6.04 6.10 7.48 7.70
1 0 5 .7 1 0 0 .9 9 7 .2 9 6 .3 7 .0 5 .8 5 .6 5 .4 5 .4
1 2 .2 1 3 .9 1 4 .2 1 3 .1 2 .0 1 .5 1 .2 0 .7 0 .7
4 .6 5 .3 5 .4 4 .9 0 .8 0 .6 0 .5 0 .3 0 .3
Trial B Trial B Trial B T rial B Trial B Trial B Trial B Trial B Trial B
Blood
Glucose
7
Blood
Glucose
8
Blood
Glucose
9
Blood
Glucose
10
Blood
Glucose
Pre
(mM)
Blood
Glucose
1
Blood
Glucose
2
Blood
Glucose
3
Blood
Glucose
4
124.50 118.75 114.50 110.33 7.33 6.78 7.78 7.58 7.31
192.67 206.92 193.42 187.58 9.70 6.72 10.04 8.51 8.44
117.42 116.08 117.00 111.67 7.46 7.97 7.22 6.88 6.66
109.08 105.75 96.42 91.58 7.31 6.37 6.08 6.14 6.03
91.08 93.58 104.75 103.33 7.09 6.29 5.76 5.60 5.31
102.67 98.92 93.92 87.83 8.44 6.98 6.62 6.47 6.38
86.00 76.67 78.42 81.67 9.26 6.88 7.01 6.54 5.64
1 1 7 .6 1 1 6 .7 1 1 4 .1 1 1 0 .6 7 .9 6 .9 7 .3 6 .9 6 .7
3 5 .8 4 2 .3 3 7 .4 3 5 .8 1 .0 0 .6 1 .6 1 .0 1 .1
1 3 .5 1 6 .0 1 4 .1 1 3 .5 0 .4 0 .2 0 .6 0 .4 0 .4
1 1 0
Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Blood Blood Blood Blood Blood Blood Blood
Glucometer
Reading Glucometer
Glucose Glucose Glucose Glucose Glucose Glucose Glucose Pre Reading
5 Lunch 6 7 8 9 10 (mg/dL) Lunch
5.39 7.26 6.08 5.68 5.44 5.28 5.22 160 102
4.56 4.92 4.69 4.60 4.58 4.52 4.51 128 91
6.33 7.08 6.83 6.45 6.38 6.15 5.98 108 101
5.56 5.80 5.89 5.59 4.63 4.31 4.27 128 115
5.37 5.44 6.13 5.99 5.82 5.85 5.96 140 108
6.03 6.60 5.57 6.17 5.88 5.29 5.43 121 110
7.25 7.69 6.20 6.62 6.52 6.40 6.06 167 103
5 .5 6 .2 5 .9 5 .7 5 .5 5 .2 5 .2 1 3 6 1 0 4
0 .6 0 .9 0 .7 0 .6 0 .7 0 .7 0 .7 2 1 .2 7 .7
0 .3 0 .4 0 .3 0 .3 0 .3 0 .3 0 .3 8 .0 2 .9
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
Blood Blood Blood Blood Blood Blood Blood
Glucometer
Reading Glucometer
Glucose Glucose Glucose Glucose Glucose Glucose Glucose Pre Reading
5 Lunch 6 7 8 9 10 (mg/dL) Lunch
6.96 7.20 6.44 6.92 6.60 6.36 6.13 117 125
6.14 11.02 10.41 10.70 11.50 10.75 10.42 179 99
6.13 6 24 6.33 6.52 6.45 6.50 6.20 118 128
5.86 5.77 5.69 6.06 5.88 5.36 5.09 118 101
5.24 5.36 4.90 5.06 5.20 5.82 5.74 112 128
6.06 6.73 5.59 5.70 5.50 5.22 4.88 137 124
5.71 6.29 4.49 4.78 4.26 4.36 4.54 141 144
6 .1 7 .1 6 .6 6 .8 6 .9 6 .7 6 .4 1 3 2 1 2 1
0 .6 2 .1 2 .0 2 .0 2 .3 2 .1 2 .0 2 3 .6 1 6 .0
0 .2 0 .8 0 .8 0 .8 1 .0 . 0 . 8 0 .8 8 .9 6 .0
I l l
Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Glucometer Glucometer Glucometer Glucometer
Reading Reading Reading Reading
Post Pre (mM) Lunch Post RPE 1 RPE 3 RPE 5 RPE 6
82 8.9 5.7 4.6 12 12 11 12
78 7.1 5.1 4.3 9 7 8 8
99 6.0 5.6 5.5 11 11 11 11
94 7.1 6.4 5.2 11 11 11 11
107 7.8 6.0 5.9 12 12 13 12
82 6.7 6.1 4.6 10 10 10 11
90 9.3 5.7 5.0 7 7 7 7
9 0 7 .6 5 .8 5 .0 1 0 1 0 1 0 1 0
1 0 .5 1 .2 0 .4 0 .6 1 .8 2 .2 2 .0 2 .0
4 .0 0 .4 0 .2 0 .2 0 .7 0 .8 0 .8 0 .7
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
Glucometer Glucometer Glucometer Glucometer
Reading Reading Reading Reading
Post Pre (mM) Lunch Post RPE 1 RPE 3 RPE 5 RPE 6
100 6.5 6.9 5.6 10 10 10 10
90 9.9 5.5 5.0 7 7 7 7
98 6.6 7.1 5.4 11 11 11 11
88 6.6 5.6 4.9 11 10 11 11
106 6.2 7.1 5.9 11 11 11 11
102 7.6 6.9 5.7 9 9 11 12
96 7.8 8.0 5.3 7 7 7 7
9 7 7 .3 6 .7 5 .4 9 9 1 0 1 0
6 .4 1 .3 0 .9 0 .4 1 .8 1 .7 1 .9 2 .0
2 .4 0 .5 0 .3 0 .1 0 .7 0 .6 0 .7 0 .8
1 1 2
Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
RPE 8 RPE 10
V02 
(L/min) 
TM 1
V02
(L/min)
TM3
V02
(L/min)
TM5
V02
(L/min)
TM6
V02
(L/min)
TM8
V02 
(L/min) 
TM 10
VC02 
(L/min) 
TM 1
13 13.5 2.02 1.72 1.81 1.85 1.67 1.55 1.85
8 10 1.83 1.70 1.76 1.83 1.87 1.91 1.60
11 11 1.76 1.68 1.71 1.73 1.73 1.74 1.54
11 12 2.03 2.00 2.11 2.11 2.03 2.11 1.73
13 13 2.20 2.13 2.22 2.21 2.24 2.36 1.89
13 13 1.99 191 1.87 1.96 1.97 2.00 1.84
7 10 1.68 1.60 1.59 1.66 1.60 1.63 1.56
11 1 2 1 .9 1 .8 1 .9 1 .9 1 .9 1 .9 1 .7
2 .5 1 .5 0 .2 0 .2 0 .2 0 .2 0 .2 0 .3 0 .1
0 .9 0 .6 0 .1 0 .1 0 .1 0 .1 0 .1 0 .1 0 .1
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
RPE 8 RPE 10
V02 
(L/min) 
TM 1
V02
(L/min)
TM3
V02
(L/min)
TM5
V02
(L/min)
TM6
V02
(L/min)
TM8
V02 
(L/min) 
TM 10
VC02 
(L/min) 
TM 1
11 10 1.71 1.71 1.62 1.71 1.73 1.68 1.56
8 9 1.68 1.69 1.64 1.73 1.71 1.81 1.51
11 11 1.80 1.68 1.64 1.69 1.68 1.69 1.59
13 12 2.03 1.95 1.86 1.98 1.97 1.99 1.81
11 11 2.40 2.20 2.22 2.24 2.28 2.32 2.13
13 13 1.88 1.82 1.83 1.95 191 1.97 1.75
7 8 1.78 1.63 1.66 1.68 1.68 1.68 1.65
11 11 1 .9 1 .8 1 .8 1 .9 1 .9 1 .9 1 .7
2 .3 1 .7 0 .3 0 .2 0 .2 0 .2 0 .2 0 .2 0 .2
0 .9 0 .6 0 .1 0 .1 0 .1 0 .1 0 .1 0 .1 0 .1
113
Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
VC02
(L/min)
TM3
VC02 
(L/min) 
TM 5
VC02
(L/min)
TM6
VC02
(L/min)
TM8
VC02 
(L/min) 
TM 10
RERTM
1
RER TM
3
RERTM
5
RER TM 
6
1.42 1.48 1.63 1.38 1.22 0.92 0.83 0.82 0.88
1.44 1.40 1.47 1.47 1.45 0.87 0.85 0.80 0.80
1.46 1.44 1.52 1.43 1.36 0.87 0.87 0.84 0.87
1.64 1.63 1.72 1.60 1.57 0.85 0.82 0.77 0.82
1.79 1.76 1.87 1.79 1.81 0 86 0.84 0.79 0.85
1 7 2 1.54 1.71 1.60 1.58 0.92 0.90 0.82 0 87
1.44 1.42 1.52 1.40 1.33 0.93 0.90 0.89 0.91
1 .6 1 .5 1 .6 1 .5 1 .5 0 .9 0 .9 0 .8 0 .9
0 .2 0 .1 0 .1 0 .1 0 .2 0 .0 0 .0 0 .0 0 .0
0 .1 0 .0 0 .1 0 .1 0 .1 0 .0 0 .0 0 .0 0 .0
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
VC02 
(L/min) 
TM 3
VC02
(L/min)
TM5
VC02
(L/min)
TM6
VC02 
(L/min) 
TM 8
VC02 
(L/min) 
TM 10
RERTM
1
RER TM
3
RER TM 
5
RERTM
6
1.60 1.51 1.58 1.56 1.54 0.91 0.93 0.93 0.92
1.56 1.46 1.58 1.57 1.61 0.90 0.92 0.89 0.92
1.52 1.50 1.54 1.50 1 4 8 0.88 0.91 0.91 0.92
1.78 1.67 1 7 3 1.75 1.73 0.89 0.91 0.90 0.88
1.98 1.93 1.95 1.94 1.95 0.88 0.90 0.87 0.87
1.70 1.68 1.79 1.78 1.78 0.93 0.93 0.92 0.92
1.51 1.52 1.56 1.56 1.56 0.93 0.93 0.92 0.93
1 .7 1 .6 1 .7 1 .7 1 .7 0 .9 0 .9 0 .9 0 .9
0 .2 0 .2 0 .2 0 .2 0 .2 0 .0 0 .0 0 .0 0 .0
0 .1 0 .1 0 .1 0 .1 0 .1 0 .0 0 .0 0 .0 0 .0
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Trial A Trial A Trial A Trial A
RERTM
8
RERTM
10
g/min 
CHO 1
g/min 
CHO 3
g/min 
CHO 5
g/min 
CHO 6
g/min 
CHO 8
g/min 
CHO 10
Total g 
CHO on 
TM
0.83 0.79 1.94 0.95 0.95 1.48 0.92 0.57 226.89
0.79 0.75 1.41 1.11 0.73 0.83 0.70 0.43 173.48
0.83 0.78 1.34 1.23 1.06 1.33 0.99 0.58 217.82
0.79 0.75 1.35 1.07 0.66 1.06 0.78 0.39 177.44
0.80 0.76 1.53 1.31 0.87 1.42 0.93 0.63 223.38
0.81 0.79 1.97 1.68 0.98 1.47 0.94 0.76 260.26
0 88 0.82 1.71 1.40 1.36 1.58 1.24 0.84 271.27
0 .8 0 .8 1 .6 1 .3 0 .9 1 .3 0 .9 0 .6 2 2 1 .5
0 .0 0 .0 0 .3 0 .2 0 .2 0 .3 0 .2 0 .2 3 7 .1
0 .0 0 .0 0 .1 0 .1 0 .1 0 .1 0 .1 0 .1 1 4 .0
Trial B Trial B Triai B Trial B Trial B Trial B Trial B Trial B Trial B
RER TM 
8
RERTM
10
g/min 
CHO 1
g/mIn 
CHO 3
g/min 
CHO 5
g/min 
CHO 6
g/min 
CHO 8
g/min 
CHO 10
Total g 
CHO on 
TM
0.91 0.92 1.61 1.78 1.66 1.68 1.58 1.61 330.60
0.92 0.89 1.48 1.66 1.37 1.66 1.66 1.53 312.02
0.89 0.87 1.44 1.53 1.55 1.61 1.43 1.29 294.77
0.89 0.87 1.71 1.83 1.61 1.53 1.63 1.47 326.37
0.85 0.84 1.95 1.92 1.66 1.71 1.51 1.41 338.81
0.93 0.90 1.92 1.86 1 7 8 1.88 1.97 1.76 371.99
0.93 0.92 1.79 1.67 1.59 1.74 1.70 1.68 338.76
0 .9 0 .9 1 .7 1 .8 1 .6 1 .7 1 .6 1 .5 3 3 0 .5
0 .0 0 .0 0 .2 0 .1 0 .1 0 .1 0 .2 0 .2 2 4 .1
0 .0 0 .0 0 .1 0 .1 0 .0 0 .0 0 .1 0 .1 9 .1
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
g/min 
FAT 1
g/min 
FAT 3
g/min
FATS
g/min 
FAT 6
g/min
FATS
g/min 
FAT 10
Total g 
FAT on 
TM
Total
Water
consumed
(L)
Total 
Void (L)
0.28 0.50 0.54 0.37 0.48 0.56 90.79 2.5 2.4
0.38 0.43 0.60 0.60 0.66 0.78 115.12 1.65 0.65
0.37 0 38 0.45 0.36 0.49 0.64 89.71 3.5 3.3
0.50 0.59 0.79 0.65 0.71 0.89 138.02 1.85 1.55
0.52 0 57 0.77 0.57 0.76 0.93 137.04 2 0.7
0.26 0.32 0.56 0.43 0.62 0.70 96.39 5.6 3.65
0.20 0.27 0.28 0.24 0.33 0.49 60.49 7.9 7.4
0 .4 0 .4 0 .6 0 .5 0 .6 0 .7 1 0 3 .9 3 .6 2 .8
0 .1 0 .1 0 .2 0 .1 0 .2 0 .2 2 8 .0 2 .3 2 .3
0 .0 0 .0 0 .1 0 .1 0 .1 0 .1 1 0 .6 0 .9 0 .9
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
g/min 
FAT 1
g/min 
FAT 3
g/min 
FAT 5
g/min 
FAT 6
g/min
FATS
g/min 
FAT 10
Total g 
FAT on 
TM
Total
Water
consumed
(L)
Total 
Void (L)
0.25 0.19 0.19 0.23 0.27 0.23 45.25 2.3 2.3
0.28 0.22 0.30 0.24 0.23 0.33 53.53 1 0.65
0.36 0.27 0.24 0.24 0.30 0.36 58.76 4.4 3.4
0.37 0.29 0.32 0.41 0.37 0.44 73.36 1.8 2.25
0.47 0.38 0.48 0.47 0.57 0.62 99.71 1.35 1.15
0.22 0.21 0.25 0.27 0.21 0.33 49.69 5.4 4.45
0.22 0.19 0.23 0.19 0.21 0.21 41.43 7 4.93
0 .3 0 .2 0 .3 0 .3 0 .3 0 .4 6 0 .2 3 .3 2 .7
0 .1 0 .1 0 .1 0 .1 0 .1 0 .1 2 0 .3 2 .3 1 .6
0 .0 0 .0 0 .0 0 .0 0 .0 0 .1 7 .7 0 .9 0 .6
1 1 6
First A ssay Run
Trial A Trial A Trial A Trial A Trial A Trial A
Urine
Nitrogen
(mg/dL)
Protein
Metabolism
Time Bkfst 
to Exer 
(min)
Time Exer to 
post biopsy 
(min)
Muscle
Glycogen
pre
Muscle
Glycogen
post
416 15:25:00 17:36:00 197.41 117.3
1353 26:01:00 14:33:00 83.93 50.49
261 31:35:00 15:26:00 214.32 104.74
675 26:48:00 14:17:00 206.1 152.48
1116 29:50:00 15:42:00 108.94 107.09
278 24:46:00 16:46:00 184.32 97.92
169 7:32:00 17:38:00 211.59 135.42
6 0 9 .7 #D IV /0! 2 3 : 0 8 :0 9 1 5 :5 9 :4 3 1 7 2 .4 1 0 9 .3
4 6 1 .2 #D IV /0! 8 :3 5 :5 5 1 :2 2 :1 5 5 3 .3 3 2 .2
1 7 4 .3 #D IV /0! 3 : 1 5 : 0 0 0 : 3 1 : 0 5 2 0 .1 1 2 .2
Trial B Trial B Trial B Trial B Trial B Trial B
Urine
Nitrogen
(mg/dL)
Protein
Metabolism
Time Bkfst 
to Exer 
(min)
Time Exer to 
post biopsy 
(min)
Muscle
Glycogen
pre
Muscle
Glycogen
post
470 24:05:00 16:31:00 178.16 131.78
1389 16:54:00 16:38:00 108.34 53.17
180 29:31:00 17:05:00 225.54 216.89
387 20:47:00 15:05:00 207.03 149.93
580 31:25:00 19:05:00 166.52 160.57
189 23:44:00 14:30:00 130.52 114.34
186 25:52:00 17:52:00 211.59 181.72
4 8 3 .0 #D IV /0! 2 4 :3 6 :5 1 1 6 :4 0 :5 1 1 7 5 .4 1 4 4 .1
4 2 9 .4 #D IV /0! 4 : 5 7 : 0 6 1 :3 3 :5 1 4 3 .6 5 2 .2
1 6 2 .3 #D IV /0! 1 :5 2 :1 8 0 : 3 5 : 2 8 1 6 .5 1 9 .7
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L arger  n u m b e r 2 n d  A s s a y  R un Difference Between Assays
Trial A Trial A
Muscle Muscle
Glycogen Glycogen
pre post
205.13 136.00
83.93 51.32
214.32 114.09
206.10 152.48
128.59 107.09
186.05 122.44
211.59 135.42
176.5 117.0
50.5 32.7
19.1 12.4
Trial B Trial B
Muscle Muscle
Glycogen Glycogen
pre post
178.16 152.00
109.81 83.21
225.54 216.89
207.03 149.93.
169.87 172.71
150.04 126.19
211.59 181.72
178.9 154.7
40.3 42.6
15.2 16.1
Trial A Trial A
Muscle
Glycogen
pre
Muscle
Glycogen
post
205.13 136.00
71.50 51.32
183.46 114.09
185.38 114.21
128.59 95.05
186.05 122.44
160.0 105.5
50.5 29.7
19.1 11.2
Trial B Trial B
Muscle
Glycogen
pre
Muscle
Glycogen
post
157.31 152.00
109.81 83.21
222.44 154.80
195.07 136.41
169.87 172.71
150.04 126.19
167.4 137.6
38.8 31.1
14.7 11.7
Trial A Trial A
Muscle
Glycogen
pre
Muscle
Glycogen
post
7.72 18.70
-12.43 0.83
-30.86 9.35
-20.72 -38.27
19.65 -12.04
1.73 24.52
-5.8 0.5
18.9 23.0
7.1 8.7
Trial B Trial B
Muscle
Glycogen
pre
Muscle
Glycogen
post
-20.85 20.22
1.47 30.04
-3.10 -62.09
-11.96 -13.52
3.35 12.14
19.52 11.85
-1.9 -0.2
13.9 33.6
5.2 12.7
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Average of Assays Diff btwn run 1 and avg Pre-Post
Trial A Trial A
Muscle Muscle
Glycogen Glycogen
pre post
201.27 126.65
77.72 50.91
198.89 109.42
195.74 133.35
118.77 101.07
185.19 110.18
211.59 135.42
1 6 9 .9 1 0 9 .6
5 1 .0 2 9 .0
1 9 .3 1 1 .0
Trial B Trial B
Muscle Muscle
Glycogen Glycogen
pre post
167.74 141.89
109.08 68.19
223.99 185.85
201.05 143.17
168.20 166.64
140.28 120.26
211.59 181.72
1 7 4 .6 1 4 4 .0
4 1 .0 4 0 .8
1 5 .5 1 5 .4
Diff btwn run 1 and avg
-3.86 -9.35
6.22 -0.41
15.43 -4 68
10.36 19.14
-9.83 6.02
-0.87 -12.26
2 .9 -0 .3
9 .4 1 1 .5
3 .6 4 .3
Trial B Trial B
10.43 -10.11
-0.73 -15.02
1.55 31.05
5.98 6.76
-1.67 -6.07
-9.76 -5.92
1 .0 0 .1
6 .9 1 6 .8
2 .6 6 .3
Trial A
Muscle
Glycogen
Difference
-74.62
-26.81
-89.48
-62.40
-17.69
-75.01
-5 7 .7
2 8 .9
1 0 .9
Trial B
Muscle
Glycogen
Difference
-25.85
-40.89
-38.15
-57.88
-1 5 6
- 20.02
-3 0 .7
1 9 .4
7 .3
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Baseline Testing
Subject
# Age
Height
(cm)
Weight
(kg)
% Body 
Fat
PPM
(kg) PM (kg)
TM
V02max
(L/min)
TM
V02max
(ml/kg/min)
1 29 176.5 71.2 5.9 67.0 4.2 3.95 55.5
2 23 170.2 82.3 14.3 70.5 11.8 4.14 50.3
3 20 167.6 62.5 6.2 58.6 3.9 4.15 66.4
4 37 185.4 77.8 8.9 70.9 6.9 4.96 63.8
5 30 185.4 85.6 16.3 71.6 14.0 5.14 60.0
6 23 193 91.1 9.3 82.6 8.5 5.16 56.6
7 21 185 68.7 7.8 63.3 5.4 3.83 55.7
Age
Height
(cm)
Weight
(kg)
% B o d y  
Fat
PPM
(kg) PM (kg)
TM
V02max
(L/min)
TM
V02max
(ml/kg/min)
Mean 2 6 .1 1 8 0 .4 7 7 .0 9 .8 6 9 .2 7 .8 4 .5 5 8 .3
S D 6.1 9 .2 1 0 .1 4 .0 7 .5 3 .9 0 .6 5 .5
S td
E rro r 2 .3 3 .5 3 .8 1 .5 2 .9 1 .5 0 .2 2 .1
1 2 0
Baseline
Baseline "resting Baseline 1resting Testing
TM
V02vt
(Umin)
TM V02vt 
(ml/kg/min)
%V02peak
atVTTM
TM 70% 
V02vt 
(L/min)
TM 70% 
V02vt 
(ml/kg/min)
TM VT % 
grade
TM 70% 
grade
CYCLE
V02max
2.6 36.5 65.8 1.82 25.6 12 4.5 3.81
2.43 29.5 58.7 1.7 20.7 10 3 3.53
2.48 39.7 59.8 1.73 27.7 15 7.5 4.01
2.94 37.8 59.3 2.06 26.5 14 7 4.36
3.25 38.0 63.2 2.27 26.5 14 6.5 4.84
2.7 29.6 52.3 1.89 20.7 10 4 5.05
2.41 35.1 62.9 1.69 24.6 13 5 4.43
TM
V02vt
(L/min)
TM V02vt 
(ml/kg/min)
%V02peak
atVTTM
TM 70% 
V02vt
TM 70% 
V02vt 
(ml/kg/min)
TM VT % 
grade
TM 70% 
grade
CYCLE
V02max
2 .6 9 3 5 .2 6 0 .3 1 .9 2 4 .6 13 5 4 .3
0 .3 1 4 .1 4 .3 0 .2 2 .8 2.0 1.7 0 .5
0 .1 2 1 .5 1 .6 0 .1 1 .1 0.8 0.6 0 .2
1 2 1
B a s e l in e  1r e stin g
Cycle
V02max
(ml/kg/min)
CYCLE
V02vt
Cycle
V02vt
(ml/kg/min)
%
V02peak
atVT
Cycle
CYCLE
70%
V02vt
(L/min)
Cycle 70% 
V02vt 
(ml/kg/min)
CYCLE 
VT Watts
CYCLE
70%
Watts
53.5 2.33 32.7 61.2 1.63 22.9 190 95
42.9 2.00 24.3 56.7 1.4 17.0 160 60
64.2 2.39 38.2 59.6 1.68 26.9 210 110
56.0 2.24 28.8 51.4 1.57 20 2 190 110
56.5 2.79 32.6 57.6 1.95 22.8 230 95
55.4 3.28 36.0 65.0 2.3 25.2 280 120
64.5 2.53 36.8 57.1 1.77 25.8 280 135
Cycle
V02max
(ml/kg/min)
CYCLE
V02vt
Cycle
V02vt
(ml/kg/min)
%
V02peak
atVT
Cycle
CYCLE
70%
V02vt
Cycle 70% 
V02vt 
(ml/kg/min)
CYCLE 
VT Watts
CYCLE
70%
Watts
56.2 2.5 32.8 58.4 1.8 23.0 220.0 103.6
7.3 0.4 4.9 4.2 0.3 3.5 46.2 23.8
2.7 0.2 1.9 1.6 0.1 1.3 17.5 9.0
1 2 2
Trial A Trial A Trial A Trial A Trial A Trial A T rial A T ria l A
Subject
#
V02 
(L/min) 
TM 1
V02
(L/min)
TM3
V02
(L/min)
TM5
V02
(L/min)
TM6
V02
(L/min)
TM8
V02 
(L/min) 
TM 10
V 0 2
(L/min)
TM
average
V 0 2
(m l/kg/m in)
TM
average
1 2.02 1.72 1.81 1.85 1.67 1.55 1 .7 7 2 4 .8 5
2 1.83 1.70 1.76 1.83 1.87 1.91 1 .8 2 2 2 .0 9
3 1.76 1.68 1.71 1.73 1.73 1.74 1 .7 2 2 7 .6 0
4 2.03 2.00 2.11 2.11 2.03 2.11 2 .0 7 2 6 .5 5
5 2.20 2.13 2.22 2.21 2.24 2.36 2 .2 3 2 6 .0 1
6 1.99 1.91 1.87 1.96 1.97 2.00 1 .9 5 2 1 .4 2
7 1.68 1.60 1.59 1.66 1.60 1.63 1 .6 3 2 3 .6 9
Trial B Trial B Trial B Trial B Trial B Trial B T ria l B T ria l 8
Subject
#
V02 
(L/min) 
TM 1
V02
(L/min)
TM3
V02
(L/min)
TM5
V02
(L/min)
TM6
V02
(L/min)
TM8
V02 
(L/min) 
TM 10
V 0 2
(L/m in)
TM
average
V 0 2
(m l/kg/m in)
TM
average
1 1.71 1.71 1.62 1.71 1.73 1.68 1 .6 9 2 3 .7 9
2 1.68 1.69 1.64 1.73 1.71 1.81 1 .7 1 2 0 .7 6
3 1.80 1.68 1.64 1.69 1.68 1.69 1 .7 0 2 7 .1 6
4 2.03 1.95 1.86 1.98 1.97 1.99 1 .9 6 2 5 .2 4
5 2.40 2.20 2.22 2.24 2.28 2.32 2 .2 8 2 6 .6 1
6 1.88 1.82 1.83 1.95 1.91 1.97 1 .8 9 2 0 .7 8
7 1.78 1 6 3 1.66 1.68 1.68 1.68 1 .6 9 2 4 .5 3
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Trial A T ria l A T ria l A
V 0 2  
(L/min) 
C ycle 1
V 0 2
(L/m in)
C y c le
a v e r a g e
V 0 2
(m l/kg/m in)
C y cle
a v e r a g e
1 .5 6 1 .5 6 2 1 .9 5
1 .5 4 1 .5 4 1 8 .6 6
1 .7 5 1 .7 5 2 8 .0 7
1 .7 4 1 .7 4 2 2 .4 1
2 .0 3 2 .0 3 2 3 .7 6
2 .2 1 2 .2 1 2 4 .2 7
1 .7 9 1 .7 9 2 6 .1 3
Trial B T ria l B T ria l B
V 0 2  
(L/min) 
C ycle 1
V 0 2
(L/m in)
C y c le
a v e r a g e
V 0 2
(m l/kg/m in)
C y cle
a v e r a g e
1 .5 6 1 5 6 2 1 .9 5
1 .5 4 1 .5 4 1 8 .6 6
1 .7 5 1 .7 5 2 8 .0 7
1 .7 4 1 .7 4 2 2 .4 1
2 .0 3 2 .0 3 2 3 .7 6
2 .2 1 2 .2 1 2 4 .2 7
1 .7 9 1 .7 9 2 6 .1 3
W h o le
T ria l
T r e a d m ill
V 0 2
(L/m in)
TM
TM
V 0 2 m a x % T M
a v e r a g e (L/m in) M AX
1 .7 3 3 .9 5 4 3 .8 4
1 .7 6 4 .1 4 4 2 .5 9
1 .7 1 4 .1 5 4 1 .2 3
2 .0 1 4 .9 6 4 0 .6 1
2 .2 5 5 .1 4 4 3 .8 2
1 .9 2 5 .1 6 3 7 .2 5
1 .6 6 3 .8 3 4 3 .2 4
Mean
S D
S td
E rror
% T M
M AX % TM  VT
% C y c le  
M AX
4 3 .8 4 6 6 .6 0 4 1 .0 2
4 2 .5 9 7 2 .5 6 4 3 .5 0
4 1 .2 3 6 8 .9 9 4 3 .7 5
4 0 .6 1 6 8 .5 2 3 9 .9 9
4 3 .8 2 6 9 .3 0 4 2 .0 2
3 7 .2 5 7 1 .1 9 4 3 .7 7
4 3 .2 4 6 8 .7 2 4 0 .5 2
4 1 .8 0 6 9 .4 1 4 2 .0 8
2 .3 6 1 .9 3 1 .6 1
0 .8 9 0 .7 3 0 .6 1
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TM
V 02vt
(L/min)
% T M
VT
V 0 2  
(m l/kg/m in)  
TM a v e r a g e
TM
V 02m ax
(ml/kg/min) % TM  M AX
TM V 02vt 
(ml/kg/min) % TM  VT
2.60 6 6 .6 0 2 4 .3 2 55.48 4 3 .8 4 36.52 6 6 .6 0
2.43 7 2 .5 6 2 1 .4 2 50.30 4 2 .5 9 29.53 7 2 .5 6
2.48 6 8 .9 9 2 7 .3 8 66.40 4 1 .2 3 39.68 6 8 .9 9
2.94 6 8 .5 2 2 5 .8 9 63.75 4 0 .6 1 37.79 6 8 .5 2
3.25 6 9 .3 0 2 6 .3 1 60.05 4 3 .8 2 37.97 6 9 .3 0
2.70 7 1 .1 9 2 1 .1 0 56.64 3 7 .2 5 29.64 7 1 .1 9
2.41 6 8 .7 2 2 4 .1 1 55.75 4 3 .2 4 35.08 6 8 .7 2
% C y c le  
VT
6 7 .0 7
7 6 .7 9
7 3 .4 0
7 7 .8 5
7 2 .8 9
6 7 .4 0
7 0 .9 5
7 2 .3 3
4 .2 0
1 .5 9
125
W h o le
T ria l
V 0 2
(L/m in)
C y c le
a v e r a g e
C Y C L E
V 0 2 m a x
% C y c le  
M AX
C Y C L E
V 0 2 v t
%
C y c le
VT
V 0 2
(m l/kg/m in)
C y cle
a v e r a g e
C y c le
V 0 2 m a x
(m l/kg/m in )
%
C y c le
M AX
1 .5 6 3 .8 1 4 1 .0 2 2  3 3 6 7 .0 7 2 1 .9 5 5 3 .5 1 4 1 .0 2
1 .5 4 3 .5 3 4 3 .5 0 2 .0 0 7 6 .7 9 1 8 .6 6 4 2 .8 9 4 3 .5 0
1 .7 5 4 .0 1 4 3 .7 5 2 .3 9 7 3 .4 0 2 8 .0 7 6 4 .1 6 4 3 .7 5
1 .7 4 4 .3 6 3 9 .9 9 2 .2 4 7 7 .8 5 2 2 .4 1 5 6 .0 4 3 9 .9 9
2 .0 3 4 .8 4 4 2 .0 2 2 .7 9 7 2 .8 9 2 3 .7 6 5 6 .5 4 4 2 .0 2
2 .2 1 5 .0 5 4 3 .7 7 3 .2 8 6 7 .4 0 2 4 .2 7 5 5 .4 3 4 3 .7 7
1 .7 9 4 .4 3 4 0 .5 2 2 .5 3 7 0 .9 5 2 6 .1 3 6 4 .4 8 4 0 .5 2
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Cycle
V 02vt
(ml/kg/min)
% Cycle 
VT
32.72
24.30 7 6 .7 9
38.24 7 3 .4 0
28.79 7 7 .8 5
32.59 7 2 .8 9
36.00 6 7 .4 0
36.83 7 0 .9 5
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Subject#:
Weight Pre: kg
10-hour muscle glycogen study — Fall 2003 
Human Perform ance Lab
Trial A
_  Height:
Weight Post:________kg
cm
BF%:
VOsmax Treadmill: 
C ycle:___
_L/min
70% VT TreadmiU:
% Grade® V T :____
Watts @ V T :_______
_L/min 
 U m in
Am ount o f  drink provided:
Average Watts on UBE (each cycle);
Average SS HR on Cycle:
Average SS HR on Treadmill:
Total H2 O consumed:_________ I
Time from breakfast to exercise;
VT Treadmill: 
VT C ycle:___
L/min
70% VT Cycle: 
% Grade @ 70% VT: _
W atts @ 70% V T :_____
ml
_L/min 
 L/min
Gas collection: Hour 1 _  
Hour 3 _  
Hour 5 _  
Hour 6 _  
Hour 8 _  
Hour 10
Total V oid :___________ L
min Time from exercise to pm biopsy: mm
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Subject #:
Weight Pre: kg
10-hour muscle glycogen study — Fall 2003 
Human Performance Lab
Trial B
_  Height:
Weight Post:________kg
cm
BF%:
Treadmill: 
C ycle:___
L/min
70% VT TreadmiU:
% Grade® V T :____
Watts @ V T :_______
_L/min
L/min
Amount of drink provided:
Avereige Watts on UBE (each cycle):
Average SS HR on Cycle:
Average SS HR on Treadmill:
Total H2 O consumed:_________ I
Time from breakfast to exercise:
VT Treadmill: 
VT C ycle:___
L/min
70% VT Cycle: 
% Grade @ 70% VT: __
Watts @ 70% V T:____
ml
_L/min
L/min
Gas collection: Hour 1 _  
Hour 3 _  
Hour 5 _  
Hour 6 _  
Hour 8 _  
Hour 10
Total V oid:___________ L
min Time from exercise to pm biopsy: min
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Appendix IV
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 2455.519 409.253
Trial 1 2.957 2.957 1.963 .2107 .2107 .2107
Trial * Subject 6 9.040 1.507
Time 1 6.703 6.703 34.544 .0011 .0011 .0011
Time * Subject 6 1.164 .194
Trial * Time 1 .029 .029 .103 .7594 .7594 .7594
Trial * Time * ... 6 1.689 .281
Dependent: Body Weight (kg)
Means Table 
Effect: Trial * Time 
Dependent: Body Weight (kg)
Count Mean Std. Dev. Std. Error
A, pre 7 77.500 9.785 3.698
A, post 7 76.586 10.062 3.803
B, pre 7 78.214 10.302 3.894
B, post 7 77.171 10.397 3.930
Comparison 1 
Effect: Trial * Time 
Dependent: Body Weight (kg)
Cell Weight
Comparison 2 
Effect: Trial * Time 
Dependent: Body Weight (kg)
Cell Weight
A, pre 1.000 B, pre 1.000
A, post -1 .0 0 0 B. post -1 .000
df 1 df 1
Sum of Squares 2.926 Sum of Squares 3.806
Mean Square 2.926 Mean Square 3.806
F-Value 10.396 F-Value 13.525
P-Value .0180 P-Value .0104
G-G .0180 G-G .0104
H-F .0180 H-F .0104
Comparison 3 
Effect Trial * Time 
Dependent: Body Weight (kg)
Cell Weight
A, pre 1.000
B, pre -1 .0 0 0
df 1
Sum of Squares 1.786
Mean Square 1.786
F-Value 6.345
P-Value .0454
G-G .0454
H-F .0454
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 63.724 10.621
Trial 1 .219 .219 1.244 .3074 .3074 .3074
Trial * Subject 6 1.055 .176
Dependent: Liters drink consumed
M eans Table  
E ffect: Trial
D ep en dent: Liters drink con su m ed
Count Mean Std. Dev. Std. Error
A 7 3.571 2.350 .888
B 7 3.321 2.297 .868
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G“G H-F
Subject 6 44.665 7.444
Trial 1 .019 .019 .031 .8655 .8655 .8655
Trial * Subject 6 3.707 .618
Dependent: Total urine void
M eans T able  
E ffect: Trial
D ep en d en t: T otal urine vo id
Count Mean Std. Dev. Std. Error
A 7 2.807 2.341 .885
B 7 2.733 1.607 .607
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 1.372 .229
trial 1 6.259 6.259 95.782 .0001 .0001 .0001
trial * Subject 6 .392 .065
time 5 3.097 .619 45.322 .0001 .0001 .0001
time * Subject 30 .410 .014
trial * time 5 1.498 .300 16.123 .0001 .0001 .0001
trial * time * S... 30 .557 .019
Dependent: CHO (g/min)
M eans Table  
E ffe c t  trial * tim e  
D ep en dent: CHO (g /m in )
A,
A,
A,
A,
A,
A,
B, 
B, 
B, 
B, 
B, 
B,
1
3
5
6 
8 
10 
1
3
5
6 
8 
10
Count Mean Std. Dev. Std. Error
7 1.607 .269 .102
7 1.250 .243 .092
7 .944 .231 .087
7 1.310 .269 .102
7 .929 .171 .065
7 .600 .162 .061
7 1.700 .201 .076
7 1.750 .136 .051
7 1.603 .126 .048
7 1.687 .110 .041
7 1.640 .172 .065
7 1.536 .162 .061
Com parison 1 
E ffect: trial * tim e  
D ep en dent: O lO  (g /m in )
Cell Weight
Com parison 2  
E ffect: trial * tim e  
D ependent: CHO (g /m in )
Cell Weight
A, 1 1.000 A, 3 1-000
B, 1 -1.000 B, 3 -1.000
df 1 df 1
Sum of Squares .030 Sum of Squares .875
Mean Square .030 Mean Square .875
F-Value 1.624 F-Value 47.101
P-Value .2123 P-Value .0001
G-G .2006 GG .0001
H-F .2123 H-F .0001
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Comparison 3
Effect: trial *  time
Dependent: CHO (g/min)
Cell Weight
A, 5 1.000
B, 5 -1 .0 0 0
df 1
Sum of Squares 1.518
Mean Square 1.518
F-Value 81.713
P-Value .0001
G G .0001
H-F .0001
Comparison 4
Effect: trial *  time
Dependent: CHO (g/min)
Cell Weight
A, 6
B, 6
1.000
- 1.000
df
Sum of Squares 
Mean Square 
F-Value 
P-Value 
G“G 
H-F
1
.498
.498
26.798
.0001
.0004
.0001
C om p arison  5  
E ffe c t:  trial * t im e  
D e p e n d e n t:  CHO ( g /m in )
Cell Weight
C om p arison  6  
E ffec t: trial * t im e  
D ep en d e n t:  CHO (g /m in )
Cell Weight
A, 8 1.000 A, 10 1.000
B, 8 -1 .0 0 0 B, 10 -1 .0 0 0
df 1 df 1
Sum of Squares 1.771 Sum of Squares 3.064
Mean Square 1.771 Mean Square 3.064
F-Value 95.356 F-Value 164.958
P-Value .0001 P-Value .0001
G G .0001 G-G .0001
H-F .0001 H-F .0001
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 9119.595 1519.933
tria l 1 41559.523 41559.523 94.202 .0001 .0001 .0001
trial * Subject 6 2647.037 441.173
Dependent: total g CHO (treadmill)
M eans T ab le  
E ffect: trial 
D ep en d en t: to ta l  g  CHO (treadm ill)
Count Mean Std. Dev. Std. Error
A 7 221.506 37.132 14.035
B 7 330.474 24.131 9.121
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 .954 .159
trial 1 .999 .999 50.129 .0004 .0004 .0004
trial * Subject 6 .120 .020
time 5 .402 .080 27.955 .0001 .0001 .0001
time * Subject 30 .086 .003
trial * time 5 .201 .040 21.211 .0001 .0001 .0001
trial * time * S... 30 .057 .002
Dependent: FAT (g/min)
M eans Table 
E ffect: trial * tim e  
D ep en dent: FAT (g /m in )
A,
A.
A,
A,
A,
A,
B, 
B, 
B, 
B, 
B, 
B,
1
3
5
6 
8 
10 
1
3
5
6 
8 
10
Count Mean Std. Dev. Std. Error
7 .359 .121 .046
7 .437 .122 .046
7 .570 .177 .067
7 .460 .150 .057
7 .579 .152 .057
7 .713 .164 .062
7 .310 .093 .035
7 .250 .069 .026
7 .287 .096 .036
7 .293 .105 .040
7 .309 .129 .049
7 .360 .139 .052
Com parison 1 
E ffect: trial * tim e  
D ep en dent: FAT (g /m in )
Cell Weight
A, 1
B, 1
1.000
- 1.000
df 1
Sum of Squares .008 
Mean Square .008 
F-Value 4.363 
P-Value .0453 
G-G .0743 
H-F .0594
Comparison 2  
Effect: trial * tim e  
D ependent: FAT (g /m in )
Cell Weight
A, 3 1.000
B, 3 -1.000
df 1
Sum of Squares .123
Mean Square .123
F-Value 64.775
P-Value .0001
G-G .0001
H-F .0001
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Comparison 3
Effect: trial *  time
Dependent: FAT (g/min)
Cell Weight
A, 5
B, 5
1.000
- 1.000
df
Sum of Squares 
Mean Square 
F-Value 
P-Value 
G-G 
H-F
1
.280
.280
147.977
.0001
.0001
.0001
Comparison 4
Effect: trial *  time
Dependent: FAT (g/min)
Cell Weight
A. 6
B, 6
1.000
- 1.000
df 1
Sum of Squares .098
Mean Square .098
F-Value 51.670
P-Value .0001
G-G .0001
H-F .0001
C om p arison  5  
E ffec t:  trial * t im e  
D e p e n d e n t:  FAT (g /m in )
Cell Weight
C om p arison  6  
E ffec t: trial * t im e  
D ep en d e n t;  FAT ( g /m in )
Cell Weight
A, 8 1.000 A, 10 1.000
B, 8 -1 .0 0 0 B, 10 -1 .0 0 0
df 1 df 1
Sum of Squares .255 Sum of Squares .436
Mean Square .255 Mean Square .436
F-Value 134.830 F-Value 230.281
P-Value .0001 P-Value .0001
G-G .0001 G-G .0001
H-F .0001 H-F .0001
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G“G H-F
Subject 6 6378.403 1063.067
tria l 1 6680.856 6680.856 50.676 .0004 .0004 .0004
trial * Subject 6 791.014 131.836
Dependent: total g FAT (treadmill)
M eans T able  
E ffect: trial
D ep en d en t: to ta l  g  FAT (treadm ill)
Count Mean Std. Dev. Std. Error
A 7 103.937 27.995 10.581
B 7 60.247 20.277 7.664
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 43.467 7.245
Trial 1 28.061 28.061 1.518 .2640 .2640 .2640
Trial * Subject 6 110.881 18.480
Time 11 37.747 3.432 5.227 .0001 .0109 .0009
Time * Subject 66 43.333 .657
Trial * Time 11 4.812 .437 .424 .9403 .6217 .6697
Trial * Time * ... 66 68.146 1.033
Dependent: Blood Glucose (mM)
M eans Table  
E ffect: Trial * Tim e 
D ep en dent: Blood G lucose (mM)
Count Mean Std. Dev. Std. Error
A, pre 7 7.160 1.888 .713
A, 1 7 5.810 1.405 .531
A, 2 7 5.649 1.088 .411
A, 3 7 5.736 1.023 .387
A, 4 7 5.750 1.081 .408
A, 5 7 5.784 .855 .323
A, lunch 7 6.399 1.031 .390
A, 6 7 5.913 .660 .249
A, 7 7 5.871 .675 .255
A, 8 7 5.607 .773 .292
A, 9 7 5.400 .791 .299
A, 10 7 5.347 .727 .275
B, pre 7 8.084 1.054 .398
B, 1 7 6.856 .553 .209
B, 2 7 7.216 1.420 .537
B, 3 7 6.817 .965 .365
B, 4 7 6.539 1.067 .403
B, 5 7 6.014 .523 .198
B, lunch 7 6.944 1.895 .716
B, 6 7 6.264 1.959 .740
B, 7 7 6.534 1.986 .751
B, 8 7 6.484 2.349 .888
B, 9 7 6.339 2.077 .785
B, 10 7 6.143 1.989 .752
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Comparison 1
Effect: Trial *  Time
Dependent: Blood Glucose (mM)
Cell Weight
Comparison 2
Effect: Trial *  Time
Dependent: Blood Glucose (mM)
Cell Weight
A, pre 1.000 A, 1 1.000
B, pre -1 .000 B, 1 -1 .000
df 1 df 1
Sum of Squares 2.990 Sum of Squares 3.827
Mean Square 2.990 Mean Square 3.827
F-Value 2.896 F-Value 3.707
P-Value .0935 P-Value .0585
G G .0917 G-G .0786
H-F .0989 H-F .0830
Comparison 3 Comparison 4
Effect: Trial * Time 
Dependent: Blood Glucose (mM)
Cell Weight
Effect: Trial * Time 
Dependent: Blood Glucose (mM)
Cell Weight
A, 2 1.000 A, 3 1.000
B, 2 -1 .000 B, 3 -1 .000
df 1
Sum of Squares 8.596 
Mean Square 8.596 
F-Value 8.325 
P-Value .0053 
G-G .0408 
H-F .0386
df 1
Sum of Squares 4.093 
Mean Square 4.093 
F-Value 3.964 
P-Value .0506 
G-G .0751 
H-F .0788
Comparison 5 
Effect: Trial * Time 
Dependent: Blood Glucose (mM)
Cell Weight
Comparison 6 
Effect: Trial * Time 
Dependent: Blood Glucose (mM)
Cell Weight
A, 4 1.000 A. 5 1.000
B, 4 -1 .000 B, 5 -1 .000
df 1 df 1
Sum of Squares 2.176 Sum of Squares .185
Mean Square 2.176 Mean Square .185
F-Value 2.108 F-Value .179
P-Value .1513 P-Value .6733
GG .1091 G-G .2474
H-F .1203 H-F .2913
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Comparison 7
Effect: Trial *  Time
Dependent: Blood Glucose (mM)
Cell Weight
df 1
Sum of Squares 1.042 
Mean Square 1.042 
F-Value 1.009 
P-Value .3187 
G-G .1509 
H-F .1721
(Comparison 8
Effect: Trial * Time
Dependent: Blood Glucose (mM)
Cell W eight
A, lunch 1.000 A, 6 1.000
B, lunch -1 .000 B, 6 -1 .000
df 1
Sum of Squares .432 
Mean Square .432 
F-Value .419 
P-Value .5199 
G-G .2008 
H-F .2342
(Comparison 9  
E ffect: Trial *  T im e  
D ep en d en t: B lood G lu cose (mM )
Cell Weight
C om parison 1 0  
E ffect: Trial * Tim e  
D ep en d en t: Blood G lu cose (mM )
Cell Weight
A, 7 1.000 A, 8 1.000
B, 7 -1 .000 B, 8 -1 .000
df 1
Sum of Squares 1.538 
Mean Square 1.538 
F-Value 1.489 
P-Value .2267 
GG .1287 
H-F .1445
df 1
Sum of Squares 2.693 
Mean Square 2.693 
F-Value 2.608 
P-Value .1111 
G-G .0974 
H-F .1058
(Comparison 11 
E ffect: Trial *  T im e  
D ep en d en t: B lood G lu cose (mM )
Cell Weight
df 1
Sum of Squares 3.083 
Mean Square 3.083 
F-Value 2.986 
P-Value .0887 
G-G .0900 
H-F .0968
C om parison 1 2  
E ffect: Trial * Tim e 
D ep en d en t: Blood G lu cose (mM )
Cell Weight
A, 9 1.000 A, 10 1.000
B, 9 -1 .000 B, 10 -1 .000
df 1
Sum of Squares 2.216 
Mean Square 2.216 
F-Value 2.146 
P-Value .1477 
G-G .1081 
H-F .1191
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 3.278 .546
Trial 1 1.339 1.339 2.090 .1984 .1984 .1984
Trial * Subject 6 3.846 .641
time points 2 34.796 1 7.398 20.508 .0001 .0021 .0014
time points * Su... 12 10.180 .848
Trial * time poi... 2 2.406 1.203 1.506 .2609 .2667 .2661
Trial * time poi... 12 9.584 .799
Dependent: Glucometer (mM)
Means Table
Effect: Trial * time points 
Dependent: Glucometer (mM)
A, pre 
A, lunch
A, post
B, pre 
B, lunch 
B, post
Count Mean Std. Dev. Std. Error
7 7.557 1.189 .449
7 5.800 .416 .157
7 5.014 .564 .213
7 7.314 1.286 .486
7 6.729 .888 .336
7 5.400 .365 .138
Comparison 1
Effect Trial * time points
Dependent: Glucometer (mM)
Cell Weight
Comparison 2
Effect: Trial * time points
Dependent: Glucometer (mM)
Cell Weight
A, pre 1.000 A, lunch 1.000
B, pre -1 .000 B, lunch -1.000
df 1 df 1
Sum of Squares .206 Sum of Squares 3.018
Mean Square .206 Mean Square 3.018
F-Value .258 F-Value 3.779
P-Value .6204 P-Value .0757
GG .5168 GG .0969
H-F .5453 H-F .0917
Comparison 3
Effect Trial * time points
Dependent Glucometer (mM)
Cell Weight
A, post
B, post
1.000
- 1.000
df
Sum of Squares 
Mean Square 
F-Value 
P-Value 
GG 
H-F
1
.521
.521
.652
.4351
.3730
.3902
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 32724.350 5454.058
Trial 1 2671.118 2671.118 3.350 .1169 .1169 .1169
Trial * Subject 6 4783.744 797.291
Time 1 14463.554 14463.554 42.236 .0006 .0006 .0006
Time * Subject 6 2054.653 342.442
Trial * Time 1 1544.549 1544.549 8.271 .0282 .0282 .0282
Trial * Time * ... 6 1120.441 186.740
Dependent: glycogen
Means Table 
Effect: Trial * Time 
Dependent: glycogen
Count Mean Std. Dev. Std. Error
placebo, Pre 7 169.881 50.950 19.257
placebo. Post 7 109.571 28.980 10.953
CHO, Pre 7 174.561 40.959 15.481
CHO, Post 7 143.960 40.830 15.432
Comparison 1 
E ffect Trial * Time 
Dependent: glycogen
Comparison 2 
Effect: Trial * Time 
Dependent: glycogen
Cell Weight Cell Weight
placebo, Pre 1.000 CHO, Pre 1.000
placebo, Post -1 .0 0 0 CHO, Post -1 .0 0 0
df 1 df 1
Sum of Squares 12730.536 Sum of Squares 3277.566
Mean Square 12730.536 Mean Square 3277.566
F-Value 68.172 F-Value 17.551
P-Value .0002 P-Value .0058
G G .0002 G G .0058
H-F .0002 H-F .0058
Comparison 3 Comparison 4
Effect: Trial * Time Effect: Trial *Time
D ependent glycogen Dependent: glycogen
Cell Weight Cell Weight
placebo, Pre 1.000 placebo, Post 1.000
CHO, Pre -1 .0 0 0 CHO, Post -1 .0 0 0
df 1 df 1
Sum of Squares 76 .658 Sum of Squares 4139.008
Mean Square 76 .658 Mean Square 4139.008
F-Value .411 F-Value 22.165
P-Value .5454 P-Value .0033
G-G .5454 G-G .0033
H-F .5454 H-F .0033
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 9342.871 1557.145
Trial 1 860.064 860.064 2.895 .1398 .1398 .1398
Trial * Subject 6 1782.786 297.131
Times 9 1458.579 162.064 6.674 .0001 .0183 .0094
Times * Subject 54 1311.271 24.283
Trial * Times 9 353.436 39.271 3.545 .0016 .0432 .0129
Trial * Times * ... 54 598.214 11.078
Dependent: Cycle HR (b/min)
M eans Table 
E ffect: Trial * T im es  
D ep en dent: Cycle HR (b /m in )
Count Mean
A,
A,
A,
A,
A,
A,
A,
A,
A,
A,
B, 
B, 
B, 
B, 
B, 
B, 
B, 
B, 
B, 
B,
1
2
3
4
5
6
7
8
9
10 
1
2
3
4
5
6
7
8
9
10
Std. Dev. Std. Error
7 118.714 6.448 2.437
7 116.857 8.707 3.291
7 116.571 9.658 3.651
7 115.286 8.538 3.227
7 119.571 12.804 4.840
7 130.714 11.324 4.280
7 123.143 12.212 4.616
7 122.143 14.171 5.356
7 124.571 13.879 5.246
7 124.571 14.673 5.546
7 117.714 6.184 2.337
7 116.143 7.625 2.882
7 112.429 7.678 2.902
7 112.286 7.931 2.998
7 114.286 9.178 3.469
7 118.286 8.693 3.286
7 118.714 9.013 3.407
7 116.143 8.174 3.089
7 117.286 9.050 3.421
7 119.286 15.196 5.743
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Comparison 1
Effect: Trial *  Times
Dependent: Cyde HR (b/min)
Cell Weight
A, 1 1.000
B, 1 -1 .000
df 1
Sum of Squares 3.500
Mean Square 3.500
F-Value .316
P-Value .5764
GG .3273
H-F .4460
Comparison 2
Effect: Trial *  Times
Dependent: Cycle HR (b/min)
Cell Weight
A, 2
B, 2
1.000
■1.000
df 1
Sum of Squares 1.786 
Mean Square 1.786 
F-Value .161 
P-Value .6896 
G-G .3888 
H-F .5347
C om parison  3  
E ffect: Trial * T im es  
D ep en d en t: C y d e  HR (b /m in )
Cell Weight
C om parison 4  
E ffect: Trial * T im es  
D ep en d en t: C ycle HR (b /m in )
Cell Weight
A, 3 1.000 A, 4 1.000
B, 3 -1 .000 B, 4 -1 .000
df 1
Sum of Squares 60.071 
Mean Square 60.071 
F-Value 5.423 
P-Value .0237 
G-G .0586 
H-F .0442
df 1
Sum of Squares 31.500 
Mean Square 31.500 
F-Value 2.843 
P-Value .0975 
G-G .1109 
H-F .1127
C om parison  5  
E ffect: Trial *  T im es  
D ep en d en t: C ycle HR (b /m in )
Cell Weight
C om parison 6  
E ffect: Trial * T im es  
D ep en d en t: C ycle HR (b /m in )
Cell Weight
A, 5 1.000 A, 6 1.000
B, 5 -1 .000 B, 6 -1 .000
df 1 df 1
Sum of Squares 97.786 Sum of Squares 540.643
Mean Square 97.786 Mean Square 540.643
F-Value 8.827 F-Value 48.803
P-Value .0044 P-Value .0001
G-G .0299 G-G .0003
H-F .0155 H-F .0001
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Comparison 7
Effect; Trial *  Times
Dependent: Cycle HR (b/min)
Cell Weight
df 1
Sum of Squares 68.643 
Mean Square 68.643 
F-Value 6.196 
P-Value .0159 
G-G .0496 
H-F .0344
Comparison 8
Effect: Trial *  Times
Dependent: Cycle HR (b/min)
Cell Weight
A. 7 1.000 A, 8 1.000
B, 7 -1 .000 B, 8 -1 .000
df
Sum of Squares 
Mean Square 
F-Value 
P-Value 
G-G 
H-F
1
126.000
126.000
11.374
.0014
.0193
.0077
C om parison 9  
E ffect: Trial * T im es  
D ep en d en t: C ycle HR (b /m in )
Cell Weight
Com parison 1 0  
E ffect: Trial * T im es  
D ep en dent: C y d e  HR (b /m in )
Cell Weight
A, 9 1.000 A, 10 1.000
B. 9 -1 .000 B, 10 -1 .000
df 1 df 1
Sum of Squares 185.786 Sum of Squares 97.786
Mean Square 185.786 Mean Square 97.786
F-Value 16.771 F-Value 8.827
P-Value .0001 P-Value .0044
G-G .0085 G-G .0299
H-F .0020 H-F .0155
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Type III Sums of Squares
Source d f Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 9224.871 1537.479
T rial 1 816.029 816.029 3.749 .1010 .1010 .1010
Trial * Subject 6 1306.071 217.679
Times 9 1735.114 192.790 9.831 .0001 .0009 .0001
Times * Subject 54 1058.986 19.611
Trial * Times 9 207.829 23.092 1.766 .0965 .1990 .1551
Trial * Times * ... 54 706.071 13.075
Dependent: Treadmill HR (b/min)
M eans Table  
E ffect: Trial * T im es  
D ep en dent: Treadmill HR (b /m in )
A,
A,
A,
A,
A,
A,
A,
A,
A,
A,
B, 
B, 
B, 
B, 
B, 
B, 
B, 
B, 
B, 
B,
1
2
3
4
5
6
7
8
9
10 
1
2
3
4
5
6
7
8
9
10
Count Mean Std. Dev. Std. Error
7 120.857 10.335 3.906
7 116.143 10.090 3.814
7 114.429 9.589 3.624
7 114.857 8.591 3.247
7 118.857 10.946 4-137
7 126.857 10.558 3.991
7 121.714 14.349 5.424
7 124.429 9.607 3.631
7 124.429 10.518 3.975
7 126.714 13.961 5.277
7 118.714 8.920 3.372
7 113.857 8.375 3.166
7 113.143 8.745 3.305
7 111.714 9.587 3.623
7 114.286 8.077 3.053
7 118.143 7.904 2.988
7 115.714 9.340 3.530
7 116.857 9.651 3.648
7 117.143 9.686 3.661
7 121.429 10.952 4.140
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Comparison 1
Effect: Trial *  Times
Dependent: Treadmill HR (b/min)
Cell Weight
Comparison 2
Effect: Trial *  Times
Dependent: Treadmill HR (b/min)
Cell Weight
A, 1 1.000 A. 2 1.000
B, 1 -1 .000 B, 2 -1.000
df 1 df 1
Sum of Squares 16.071 Sum of Squares 18.286
Mean Square 16.071 Mean Square 18.286
F-Value 1.229 F-Value 1.398
P-Value .2725 P-Value .2422
G-G .1909 G-G .1781
H-F .2343 H-F .2144
(Comparison 3 Comparison 4
Effect: Trial * Times 
Dependent: Treadmill HR (b/min)
Cell Weight
Effect: Trial * Times 
Dependent: Treadmill HR (b/min)
Cell Weight
A, 3 1.000 A, 4 1.000
B, 3 -1 .000 B. 4 -1.000
df 1 df 1
Sum of Squares 5.786 Sum of Squares 34.571
Mean Square 5.786 Mean Square 34.571
F-Value .442 F-Value 2.644
P-Value .5088 P-Value .1098
GG .2918 G-G .1171
H-F .3903 H-F .1224
Comparison 5 Comparison 6
Effect: Trial * Times 
Dependent: Treadmill HR (b/min)
Cell Weight
Effect: Trial * Times 
Dependent: Treadmill HR (b/min)
Cell Weight
A, 5 1.000 A, 6 1.000
B. 5 -1 .000 B, 6 -1.000
df 1 df 1
Sum of Squares 73.143 Sum of Squares 265.786
Mean Square 73.143 Mean Square 265.786
F-Value 5.594 F-Value 20.327
P-Value .0216 P-Value .0001
G-G .0567 GG .0055
H-F .0430 H-F .0010
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Comparison 7
Effect Trial *  Times
Dependent Treadmill HR (b/min)
Cell Weight
Effect Trial * Times 
Dependent: Treadmill HR (b/min)
Cell Weight
Comparison 8
Effect: Trial * Times
Dependent: Treadmill HR (b/min)
Cell Weight
A, 7 1.000 A, 8 1.000
B, 7 -1.000 B, 8 -1.000
df 1 df 1
Sum of Squares 126.000 Sum of Squares 200.643
Mean Square 126.000 Mean Square 200.643
F-Value 9.636 F-Value 15.345
P-Value .0030 P-Value .0003
G“G .0263 G-G .0108
H-F .0131 H-F .0031
Comparison 9 Comparison 10
Effect: Trial * Times 
Dependent: Treadmill HR (b/min)
Cell Weight
A, 9 1.000 A, 10 1.000
B, 9 -1.000 B, 10 -1.000
df 1 df 1
Sum of Squares 185.786 Sum of Squares 97.786
Mean Square 185.786 Mean Square 97.786
F-Value 14.209 F-Value 7.479
P-Value .0004 P-Value .0084
G-G .0127 G-G .0388
H-F .0041 H-F .0241
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 .040 .007
trial 1 .097 .097 71.084 .0002 .0002 .0002
trial * Subject 6 .008 .001
time 5 .039 .008 44.169 .0001 .0001 .0001
time * Subject 30 .005 1.744E-4
trial * time 5 .020 .004 18.661 .0001 .0001 .0001
trial * time * S... 30 .006 2.108E-4
Dependent: RER
M eans Table  
E f f e c t  trial * tim e  
D ep en dent: RER
A,
A,
A,
A,
A,
A,
B, 
B, 
B, 
B, 
B, 
B,
1
3
5
6 
8 
10 
1
3
5
6 
8 
10
Count Mean Std. Dev. Std. Error
7 .889 .033 .013
7 .859 .032 .012
7 .819 .039 .015
7 .857 .037 .014
7 .819 .032 .012
7 .777 .026 .010
7 .903 .021 .008
7 .919 .012 .005
7 .906 .021 .008
7 .909 .023 .009
7 .903 .029 .011
7 .887 .029 .011
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Comparison 1
Effect: trial *  time
Dependent: RER
Comparison 2
Effect: trial *  time
Dependent: i^R
Cell Weight Cell Weight
A, 1 1.000 A, 3 1.000
B. 1 -1 .000 B, 3 -1 .000
df 1 df 1
Sum of Squares .001 Sum of Squares .013
Mean Square .001 Mean Square .013
F-Value 3.389 F-Value 59.774
P-Value .0756 P-Value .0001
G-G .0954 GG .0001
H-F .0756 H-F .0001
C om parison  3  
E ffect: trial * t im e  
D ep en d en t: RER
Cell Weight
df 1
Sum of Squares .027 
Mean Square .027 
F-Value 126.088 
P-Value .0001 
G-G .0001 
H-F .0001
C om parison 4  
E ffect: trial *  tim e  
D ep en d en t: RER
Cell Weight
A, 5 1.000 A, 6 1.000
B, 5 -1 .000 B, 6 -1 .000
df 1
Sum of Squares .009 
Mean Square .009 
F-Value 43.916 
P-Value .0001 
G-G .0001 
H-F .0001
C om parison  5  
E ffect: trial * t im e  
D ep en d en t: RER
Cell Weight
df 1
Sum of Squares .025 
Mean Square .025
F-Value 117.956 
P-Value .0001 
G-G .0001 
H-F .0001
C om parison 6  
E ffect: trial * t im e  
D ep en d en t: RER
Cell Weight
A, 8 1.000 A, 10 1.000
B, 8 -1 .000 B, 10 -1 .000
df 1
Sum of Squares .042 
Mean Square .042 
F-Value 200.907 
P-Value .0001 
G-G .0001 
H-F .0001
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 234.244 39.041
trial 1 9.003 9.003 4.071 .0902 .0902 .0902
trial * Subject 6 13.268 2.211
time 5 24.277 4.855 6.312 .0004 .0145 .0050
time * Subject 30 23.077 .769
trial * time 5 2.086 .417 1.611 .1873 .2102 .1873
trial * time * S... 30 7.768 .259
Dependent: RPE
M eans Table  
E ffect: trial * tim e  
D ep endent: RPE
Count Mean Std. Dev. Std. Error
A, 1 7 10.286 1.799 .680
A, 3 7 10.000 2.160 .816
A, 5 7 10.143 2.035 .769
A, 6 7 10.286 1.976 .747
A, 8 7 10.857 2.478 .937
A, 10 7 11.786 1.468 .555
B, 1 7 9.429 1.813 .685
B, 3 7 9.286 1.704 .644
B, 5 7 9.714 1.890 .714
B, 6 7 9.857 2.035 .769
B, 8 7 10.571 2.299 .869
B, 10 7 10.571 1.718 .649
153
Comparison 1
Effect: trial *  time
Dependent: RPE
Cell Weight
A, 1 1.000
B, 1 -1 .000
df 1
Sum of Squares 2.571
Mean Square 2.571
F-Value 9.931
P-Value .0037
G-G .0083
H-F .0037
Comparison 2
Effect: trial *  time
Dependent: RPE
Cell Weight
A, 3
B, 3
1.000
■1.000
df 1
Sum of Squares 1.786 
Mean Square 1.786 
F-Value 6.897 
P-Value .0135 
G-G .0226 
H-F .0135
C om parison  3  
E ffec t: trial * t im e  
D ep en d en t: RPE
Cell Weight
C om parison 4  
E ffect: trial * t im e  
D ep en d en t: RPE
Cell Weight
A, 5 1.000 A, 6 1.000
B, 5 -1 .000 B, 6 -1 .000
df 1 df 1
Sum of Squares .643 Sum of Squares .643
Mean Square .643 Mean Square .643
F-Value 2.483 F-Value 2.483
P-Value .1256 P-Value .1256
GG .1334 GG .1334
H-F .1256 H-F .1256
C om parison  5  
E ffec t: trial * t im e  
D ep en d en t: RPE
Cell Weight
A, 8
B, 8
1.000
- 1.000
df 1
Sum of Squares .286 
Mean Square .286 
F-Value 1.103 
P-Value .3019 
G-G .2802 
H-F .3019
C om parison 6  
E ffect: trial * t im e  
D ep en d en t: RPE
Cell Weight
A, 10 1.000
B, 10 -1 .000
df 1
Sum of Squares 5.161
Mean Square 5.161
F-Value 19.931
P-Value .0001
GG .0006
H-F .0001
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 26586.613 4431.102
Trial 1 238.998 238.998 9-592 .0212 .0212 .0212
Trial * Subject 6 149.494 24.916
Times 9 24.863 2.763 .577 .8097 .6245 .7272
Times * Subject 54 258.387 4.785
Trial * Times 9 30.004 3.334 .859 .5669 .4485 .4808
Trial * Times * ... 54 209.669 3.883
Dependent; UBE (watts)
M eans Table 
E ffect: Trial * T im es  
D ep en dent: UBE (w a tts )
A,
A,
A,
A,
A,
A,
A,
A,
A,
A,
B, 
B, 
B, 
B, 
B, 
B, 
B, 
B, 
B, 
B,
1
2
3
4
5
6
7
8
9
10 
1
2
3
4
5
6
7
8
9
10
Count Mean Std. Dev. Std. Error
7 27.131 14.197 5.366
7 27.853 15.767 5.959
7 28.547 1 5.089 5.703
7 27.644 15.973 6.037
7 27.944 15.661 5.919
7 27.343 15.248 5.763
7 27.406 15.495 5.857
7 27.199 15.169 5.733
7 26.930 15.352 5.802
7 27.140 16.035 6.061
7 23.200 12.881 4.868
7 24.429 14.795 5.592
7 25.156 13.892 5.251
7 24.699 14.797 5.593
7 24.910 14.796 5.592
7 24.614 15.132 5.719
7 24.857 14.851 5.613
7 25.254 15.813 5.977
7 26.144 14.786 5.589
7 25.743 15.048 5.688
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Comparison 1
Effect: Trial *  Times
Dependent: UBE (watts)
Cell Weight
Comparison 2
Effect: Trial *  Times
Dependent: UBE (watts)
Cell Weight
A, 1 1.000 A, 2 1.000
B, 1 -1.000 B, 2 -1.000
df 1 df 1
Sum of Squares 54.096 Sum of Squares 41.040
Mean Square 54.096 Mean Square 41.040
F-Value 13.932 F-Value 10.570
P-Value .0005 P-Value .0020
GG .0176 G-G .0272
H-F .0106 H-F .0193
Comparison 3 Comparison 4
Effect: Trial * Times 
Dependent: UBE (watts)
Cell Weight
Effect: Trial * Times 
Dependent: UBE (watts)
Cell Weight
A, 3 1.000 A, 4 1.000
B, 3 -1 000 B, 4 -1.000
df 1
Sum of Squares 40.256 
Mean Square 40.256 
F-Value 10.368 
P-Value .0022 
G-G .0280 
H-F .0200
df 1
Sum of Squares 30.370 
Mean Square 30.370 
F-Value 7.822 
P-Value .0071 
G-G .0407 
H-F .0331
Comparison 5 
Effect: Trial ♦ Times 
Dependent: UBE (watts)
Cell Weight
df 1
Sum of Squares 32.224 
Mean Square 32.224 
F-Value 8.299 
P-Value .0057 
G-G .0378 
H-F .0300
Comparison 6 
Effect: Trial * Times 
Dependent: UBE (watts)
Cell Weight
A, 5 1.000 A, 6 1.000
B, 5 -1.000 B, 6 -1.000
df 1
Sum of Squares 26.058 
Mean Square 26.058 
F-Value 6.711 
P-Value .0123 
G-G .0488 
H-F .0420
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Comparison 7
Effect: Trial *  Times
Dependent: UBE (watts)
Cell Weight
Effect: Trial * Times 
Dependent: UBE (w atts)
Cell Weight
Comparison 8
Effect: Trial *  Times
Dependent: UBE (watts)
Cell Weight
A. 7 1.000 A, 8 1.000
B, 7 -1 .0 0 0 B, 8 -1 .0 0 0
df 1 df 1
Sum of Squares 22.733 Sum of Squares 13.231
Mean Square 22.733 Mean Square 13.231
F-Value 5.855 F-Value 3.408
P-Value .0189 P-Value .0704
G-G .0566 G-G .0924
H-F .0509 H-F .0952
Comparison 9 (Comparison 10
Effect: Trial * Times 
Dependent: UBE (w atts)
Cell Weight
A, 9 1.000 A, 10 1.000
B, 9 -1 .0 0 0 B, 10 -1 .0 0 0
df 1 df 1
Sum of Squares 2.161 Sum of Squares 6.832
Mean Square 2.161 Mean Square 6.832
F-Value .556 F-Value 1.760
P-Value .4589 P-Value .1903
G-G .2366 G-G .1431
H-F .2907 H-F .1626
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Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F
Subject 6 3.247 .541
trial 1 .029 .029 2.117 .1959 .1959 .1959
trial * Subject 6 .083 .014
time 5 .102 .020 5.276 .0014 .0453 .0367
time * Subject 30 .115 .004
trial * time 5 .014 .003 .756 .5885 .4748 .5072
trial * time * S... 30 .108 .004
Dependent: V02 (IVmin)
M eans Table 
E ffect: trial * tim e  
D ep endent: V 0 2  ( ly m in )
A,
A,
A,
A,
A,
A,
B, 
B, 
B, 
B, 
B, 
B,
1
3
5
6 
8 
10 
1
3
5
6 
8 
10
Count Mean Std. Dev. Std. Error
7 1.930 .181 .068
7 1.820 .195 .074
7 1.867 .224 .084
7 1.907 .199 .075
7 1.873 .225 .085
7 1.900 .285 .108
7 1.897 .250 .095
7 1.811 .202 .076
7 1.781 .217 .082
7 1.854 .211 .080
7 1.851 .222 .084
7 1.877 .236 .089
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Comparison 1
Effect: trial *  time
Dependent: V02 (Lymin)
Comparison 2
Effect: trial *  time
Dependent: V02 (L/min)
Cell Weight Cell Weight
A, 1 1.000 A, 3 1.000
B. 1 -1 .000 B, 3 -1.000
df 1 df 1
Sum of Squares .004 Sum of Squares 2.5711
Mean Square .004 Mean Square 2.5711
F-Value 1.049 F-Value .071
P-Value .3140 P-Value .7912
G-G .2274 G-G .5012
H-F .2539 H-F .5852
Comparison 3 
Effect: triai * time 
Dependent: V02 (L/min)
Comparison 4 
Effect: trial * time 
Dependent: V02 (l_/min)
Cell Weight Cell Weight
A, 5 1.000 A, 6 1.000
B, 5 -1.000 B, 6 -1.000
df 1 df 1
Sum of Squares .026 Sum of Squares -010
Mean Square .026 Mean Square .010
F-Value 7.136 F-Value 2.714
P-Value .0121 P-Value .1099
G-G .0430 G-G .1233
H-F .0344 H-F .1249
Comparison 5 
Effect: triai * time 
Dependent: V02 (L/min)
Comparison 6 
Effect: trial * time 
Dependent: V02 (L/min)
Cell Weight Cell Weight
A, 8 1.000 A, 10 1.000
B, 8 -1.000 B, 10 -1.000
df 1 df 1
Sum of Squares .002 Sum of Squares .002
Mean Square .002 Mean Square .002
F-Value .446 F-Value .507
P-Value .5093 P-Value .4818
G-G .3230 G-G .3089
H-F .3734
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H-F .3559
Type III Sums of Squares
Source df Sum of Squares Mean Square F-Value P-Value G“G H-F
Subject 6 63.724 10.621
Trial 1 .219 .219 1.244 .3074 .3074 .3074
Trial * Subject 6 1.055 .176
Dependent: Urinary Nitrogen
M eans T able  
E ffect: Trial 
D ep en d en t: Urinary N itrogen
Count Mean Std. Dev. Std. Error
A 7 3.571 2.350 .888
B 7 3.321 2.297 .868
160
